

CURRICULUM VITAE

Jon B. Klein, M.D., Ph.D.
2920 Cliffwynde Trace
Louisville, Kentucky 40241
(502) 852-1155 Ofc / (502) 852-4384 – Fax
E-Mail: jon.klein@louisville.edu

EDUCATION

1971 Benjamin Franklin High School
New Orleans, Louisiana

1975 University of Texas
Austin, Texas
B.A., Biology (Honors)

1979 University of Texas Medical Branch
Galveston, Texas
M.D.

1988 University of Louisville,
Louisville, Kentucky
Ph.D., Microbiology and Immunology
Major Professor: Gerald Sonnenfeld

Post Graduate - Medical Education:

July 1979 - June 1980 Straight Medical Internship
Kansas University Medical Center
Kansas City, Kansas

July 1980 - June 1981 First Year Medical Residency
Kansas University Medical Center
Kansas City, Kansas

July 1981 - June 1982 Second Year Medical Residency
Kansas University Medical Center
Kansas City, Kansas

July 1982 - July 1985 Fellowship in Nephrology
University of Louisville School of Medicine
Louisville, Kentucky

Aug 1983 - Oct 1986 Graduate Student
University of Louisville
Department of Microbiology & Immunology
Louisville, Kentucky

Nov 1986 - Apr 1988 Doctoral Candidate
University of Louisville
Department of Microbiology & Immunology
Louisville, Kentucky

ACADEMIC APPOINTMENTS

July 1984 – 1993 Consulting Nephrologist
University of Louisville
Organ Procurement Agency
Louisville, Kentucky

July 1985 – June 1991 Assistant Professor of Medicine
University of Louisville
School of Medicine
Louisville, Kentucky

Feb 1986 – Dec 1986 1986 Acting Director
University of Louisville Histocompatibility Laboratory
Louisville, Kentucky

Nov 1986 – Present Associate in Surgery
University of Louisville
Department of Surgery
Louisville, Kentucky

July 1991 - June, 1996 Associate Professor of Medicine
University of Louisville
School of Medicine
Louisville, Kentucky

Sept 1991 – Present Associate in Department of Microbiology and Immunology
University of Louisville
School of Medicine
Louisville, Kentucky

July 1996 – Present Professor of Medicine
University of Louisville
School of Medicine
Louisville, Kentucky

Oct 2000 – Present Professor of Biochemistry & Molecular Biology
University of Louisville
School of Medicine
Louisville, Kentucky

Mar 2004 – Present James Graham Brown Foundation Endowed Chair in Proteomics
University of Louisville
James Graham Brown Cancer Center
Louisville, Kentucky

July 2013 – Present Vice-Dean for Research
University of Louisville
School of Medicine
Louisville, Kentucky

ADMINISTRATIVE RESPONSIBILITIES/OTHER POSITIONS AND EMPLOYMENT

Mar 2014 – Present University of Louisville (LCME)
Liaison Committee on Medical Education Steering Committee

July 2010 – Present Co-Director of Research Programs
Kidney Disease Program
University of Louisville
Louisville, Kentucky

July 2009 – Present Member, Clinical and Translational Research Institute
Implementation Committee
University of Louisville
Louisville, Kentucky

Mar 2003 – Present Director, Clinical Proteomics Program
University of Louisville
Louisville, Kentucky

Jan 1986 – Present Director
University of Louisville Histocompatibility Laboratory
Louisville, Kentucky

Oct 1999 – Present Director
University of Louisville Core Proteomics Laboratory
Louisville, Kentucky

Aug 2003 – 2007 Director
University of Louisville
Kentucky Proteomics Training Program
Louisville, Kentucky

July 1986 – March 1997 Co-Director University of Louisville
Adult Transplantation Program
Jewish Hospital

Aug 2013 – Present Department of Veteran Affairs
Research and Development
Million Veteran Program (MVP)
Site Principal Investigator

CERTIFICATION AND LICENSURE

Medical Licensure: Kentucky State Medical License, 1982 (Lic. #22344)
Texas State Medical License, 1979 (Inactive) (Lic. #F4168)

Board Certification: American Board of Internal Medicine
Diplomate, 1982
American Board of Internal Medicine (Nephrology)
Diplomate, 1984

SERVICE TO THE AMERICAN SOCIETY OF NEPHROLOGY

(Summary of the past 10 years)

Annual Meeting Presentations and Session Chairs

Kidney Week 2009

- Invited Speaker in Annual Meeting Session “Biomarkers in Kidney Disease”
- Co-Moderator in Annual Meeting Session “Personalized Medicine: From Here to Applications in Nephrology”

Kidney Week 2011

- Invited speaker in Annual Meeting session “Kidney Disease in Type 2 Diabetes: New Insights”
- Invited speaker in Annual Meeting session “Microparticles in Renal Disease”

Kidney Week 2013

- Co-Chair and Organizer of Annual Meeting Early Program “Novel Biomarkers of Kidney Disease: False Dawn or New Horizon?”

Kidney Week 2015

- Invited speaker in Annual Meeting session “From Systems Biology to Personalized Medicine”

Kidney Week 2016

- Invited speaker in Annual Meeting session “Biomarker Identification and Validation in the Management of CKD”
- Invited speaker in Annual Meeting session “Golden Nuggets: Role of Exosomes and Microvesicles in Kidney Diseases”

Kidney Week 2017

- Co-Moderator of Annual Meeting session “Tissue Imaging Mass Spectrometry in Nephrology”

Kidney Week 2018

- Co-Moderator of Annual Meeting session "Extracellular Vesicles in Kidney Diseases: From Trash to Treasure"

Kidney week 2020

- Co-Chair Program/Education Committee for annual nephrology meeting. Transferred the meeting to a virtual platform due to the pandemic. Over 11,000 people registered from around the world.

Committee Membership

Annual Meeting Program Committee 2013

Annual Meeting Program Committee 2019

Continuous Professional Development Committee 2019-2020

Annual Meeting Education (Program) Committee Co-Chair 2020

PROFESSIONAL MEMBERSHIPS AND ACTIVITIES

Memberships: Greater Louisville Medical Society
Kentucky Medical Association
International Society of Nephrology
American Society of Nephrology
American Association of Immunologists
Human Proteome Organization

HONORS AND AWARDS

1990 President's Initiative for Research
Young Investigator Award
University of Louisville

1990 Department of Medicine
Chairman's Research Award

2005 Genomic Technology All-Star
"One of the 50 most influential people in genomic technology"
Voted by readers of Genomic Technology magazine

July 2005 CARITAS Foundation
Award of Excellence in Research

Nov 2005 Business First
Excellence in Research

COMMITTEE ASSIGNMENTS AND ADMINISTRATIVE SERVICES

Peer Review:

National:

Sept 18-20, 1985	Participant, workshop on pathogenesis and pathophysiology of myocarditis. The National Heart, Lung and Blood Institute
Jan 9-10, 1984	Member, Surgery and Bioengineering study section (AHR), National Institutes of Health
Mar 25, 1988 1993 – 2002	Member, Ad Hoc Cardiovascular Study Section, National Institutes of Health Reviewer (Ad Hoc) Veterans Administration Merit Review Immunology Study Section
2002-2006	Member (Permanent), Veterans Administration Merit Review Immunology/Dermatology Study Section
2003-2006	Chair, Immunology B Study Section, Veterans Administration Merit Review Board
Oct 2002	Member (Ad Hoc) NIDDK General Medicine B Study Section
July 2002-July 2003 July 2005	Member, NIDDK General Medicine B Study Section Member, NIDDK Special Emphasis Panel Review Committee: George M. O'Brien Kidney Disease Core Center
July 2005 July 2003-June 2007	Member, NIH-PBKD Small Business Innovation Research (SBIR) Review Panel Permanent Member, NIH-PBKD Study Section, Ad Hoc Reviewer, NIDDK Small Business Innovative Research grants Program
Mar 2007	Member, NIDDK Study Section, George M. O'Brien Kidney Research Core Centers (P30)
Mar 2009 Mar 2009	Reviewer, Nephcure Foundation National Grants in Aid. Member, NIDDK Special Emphasis Panel Study Section,
July 2007 – Present Jan 2013	Ad Hoc reviewer, NIH-PBKD Study Section Co-Chair 2013 American Association of Clinical Chemistry (AACC) Beckman Conference-2013
Dec 2014 – Present	Member, External Expert Panel, NIDDK ASessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) study
Local and University Peer Review:	
Jan 1991 – 1997	Member, Grant Review Committee University of Louisville President's Research Initiative Fund
1992 – 1995	Member, Louisville VAMC Research Committee
1994-1995	Chairman, Louisville VAMC Research Committee
2010	Member, U of L Clinical and Translational Grant Review Committee
University, Regional, and National Committee Service:	
May 2003	Member, NHLBI "Working Group on Clinical Proteomics"
Oct 1995 – 1997	Member, Kidney-Pancreas Committee, American Society of Transplant Physicians
1989-1992	Member, National Kidney Foundation Public Policy Committee
1989-1992	Member, American Society of Nephrology Public Policy Committee
1993 – 1996	Member, Program Committee of the American Society of Transplant Physicians
1994 – 1996	Councilor, Mid-West American Federation for Clinical Research
July 1986-1995	Member, Advisory Board, Kentucky Organ Donor Association (Statewide Organ Procurement Agency)
July 1986 – 1989	Member, Steering Committee of the Louisville Institute for Heart and Lung Diseases

1994 – 2000	Member, Scientific Advisory Committee, National Institutes of Health (S10 RR016636-01) "Hybrid Quadrupole-Time of Flight Mass Spectrometer", Member Internal Advisory Board
January 2010-2013	Member, Internal Advisory Board, The Center for Environmental Genomics and Integrative Biology
2009-Present	Member, Clinical and Translational Science Institute (CTSA) Implementation Committee
2013-Present	Member, 21st Century Plan research committee
2013-Present	Member, School of Medicine Research Strategic Planning Committee
2014-Present	Health Sciences Center Space Planning Research Sub-Committee
2014-Present	Member LCME Steering Committee
2014	Chair, Associate Dean for Graduate and Post-doctoral Studies Search Committee
2019	Co-chair, University Strategic Plan "Investment" Committee
University Service:	
2016	Member, Brown Cancer Center Director Search Committee
2010	Member of the Pathology Chair Search Committee
2000 – 2003	Member of the Biochemistry Chair Search Committee
1999-2002	Research Advisory Committee to the Vice-President for Research
1999 – 2002	Member, Medical School Promotion and Tenure Committee
1994 – 1995	Dean's Committee for review of the status of Ph.D. faculty in clinical departments
Jan 1995-1996	Member, Graduate Council, University of Louisville
Community Service:	
1992-1993	Board Member, University of Louisville Hillel Foundation
1993-1995	Board Member, Kentucky Arts and Crafts Foundation
2004	Worked with State Representatives Bob DeWeese and Mary Lou Marzian to create the KY Diabetes Research Board and Diabetes Research Trust Fund
Nov 2005-2008	Education Advisory Board: Louisville Science Center of Kentucky
2007-2009	Founder, Louisville Science Café at the Louisville Science Center
2010	Member, Fischer for Mayor Leadership Policy Team for Entrepreneurship and New Technology
2012-2016	Co-Chair Partnership Together Louisville-Israel Peoplehood Platform
2016 – Present	Member Jewish Federation of Louisville board of directors
2016 – Present	Member, Jewish Heritage Fund "Jewish Life" grants committee

TEACHING

Trainees:

1. Robert Molestina, Ph.D., 1998-2000 Supported by the Core Proteomics Laboratory Fund.
2. Visith Thongboonkerd, M.D., 2001-2003, Supported by an International Society of Nephrology Fellowship Grant and the National Kidney Foundation of Thailand. Currently, Professor of Medicine, Faculty of Medicine, Mahidol University, Bangkok, Thailand
3. Michelle Barati, Ph.D. Currently an Assistant Professor at the University of Louisville
4. Jennifer Hollon, M.D. 2003. Supported by University of Louisville Kidney Disease Program
5. James Gould, B.S. 2003-July 2007. Doctorate in Biochemistry and Molecular Biology. Currently director of the Office for Post-doctoral Fellows at Harvard Medical School. Supported by a fellowship from the University of Louisville Center for Genetics and Molecular Medicine

K-Award Mentees:

1. Tongalp Tezel, KO8 2003-2007, Currently, Professor, Columbia University Department of Ophthalmology and Visual Sciences, University of Louisville
2. David Powell, KO1 2007-2010, Currently Associate Professor of Medicine, Nephrology Division, University of Louisville
3. Michelle Barati, KO1 2009-2014, Currently Assistant Professor of Medicine, Nephrology Division, University of Louisville
4. Dawn Caster, KO8 2015-2021, Currently Assistant Professor of Medicine, Nephrology Division, University of Louisville

CLINICAL ACTIVITIES

Scheduled In-Patient Responsibilities: (2002-Present) – Four months each year of renal consultative service at the Louisville Veterans Affairs Medical Center, Baptist Hospital East, Norton Suburban Hospital or Norton Audubon Hospital. For the past five years I have served exclusively at the Robley Rex VA Medical Center

Scheduled Outpatient Responsibilities: (2002-2015) – Weekly combined Renal and Primary Care Clinic at the Louisville Veterans Affairs Medical Center (2002-2005). Weekly Renal Clinic at the Louisville Veterans Affairs Medical Center (2005-Present). Kidney Transplant clinic at the U of L Kidney Disease Program (Weekly in 2002, monthly 2003-2005 and bimonthly 2005 to 2013,

GRANTS AND CONTRACTS

Funded Research: Completed Peer Reviewed:

Federal – NIH:

National Institutes of Health (Sub-contract), 1988-1989, \$40,800, "Use of monoclonal antibodies to treat acute allograft rejection," Co-Investigator.

National Institutes of Health: (R21 PA-99-131) July 2001-June 2004, \$432,000, "Cardioprotective effects of ethanol" Co-Investigator.

National Institutes of Health (R21DK629086-01) \$244,000 "Proteomic Analysis of Diabetic Nephropathy" Principal Investigator 2002-2004.

National Institutes of Health (R21DK629086-01) "Gene Expression of Persistent Chlamydia Pneumoniae". Co-Investigator 12/01/2001 – 11/30/2004.

Veterans Administration Merit Review Grant, Oct 1, 2001-Sept 30, 2004. \$325,000 "Analysis of PTH and dopamine Receptor Signaling in Proximal Tubules". Co-Investigator.

National Institutes of Health R21 "Proteomic Analysis of Neutrophil Granules". Consultant.

National Institutes of Health: (R01 HL66358-01) Oct. 2000 – Sept. 2004. \$1,008,000.00 "Proteomic Analysis of Hippocampal Hypoxic Vulnerability". Principal Investigator.

National Institutes of Health: R21HD05056401 – December, 2006 – November 2008. \$346,500 "Urinary Proteomics in Aminoglycoside Treated Newborns".

National Institutes of Health: 3P20RR018733-07S1, 2003-2007, Molecular Targets COBRE, Co-Investigator of Proteomics Core for James Graham Brown Cancer Center.

National Institutes of Health (*K01 - DK076743*) Mentored Clinical Scientists Award \$405,000. PI: David W. Powell, Ph.D. Mentor: Jon B. Klein, M.D., Ph.D.

National Institutes of Health K01DK080951 Mentored Clinical Scientists Award \$405,000. PI: Michelle Barati, Ph.D. Mentor: Jon B. Klein, M.D., Ph.D.

National Institutes of Health: 1U01DK085673-01 10/01/2009 – 04/30/2016 Award \$601,788 PI: Brad H. Rovin, M.D., FACP, FASN-Ohio State PI Subaward: Jon B. Klein, M.D., Ph.D.

National Institutes of Health R0101DK091584 09/20/2011-08/31/2016 Award \$2,673,503 PI: Michael L. Merchant, Ph.D. and Michael Brier, Ph.D. "Novel Biomarker Validation and dosing algorithms for anemia management in ESRD". Co-Investigator.

National Institutes of Health R01DK096927 04/01/2013-09/31/2018 Award \$747,585 PI: Brad H. Rovin, M.D., FACP, FASN, Ohio State University. "Discovery of Biomarkers of Kidney Pathology". Co-Investigator.

National Institutes of Health R01 DK101350-01 (Subaward) – Rush University Medical Center
PI: Jochen Reiser, M.D. – Rush University Medical Center PI Sub Award: Jon B. Klein, M.D., Ph.D.
.60 Cal Months (5%) "Role of Circulating suPAR in FSGS"

National Institutes of Health R01-DK096927 (Subaward) – Ohio State University
PI: Brad Rovin, M.D. – Ohio State University
PI Sub Award: Jon B. Klein, M.D., Ph.D.
1.32 calendar months (11%) In NCE

Federal - Veterans Administration:

Veterans Administration Merit Review Grant, 1991-1994, \$648,800, "Priming of immune cells by cytokines," Principal Investigator.

Veterans Administration Merit Review Grant, 1994-1998, \$1, 022,000, "Priming of immune cells by cytokines: Role of G protein synthesis," Principal Investigator.

Veterans Administration Merit Review Grant, Oct. 1998-Sept. 2001, \$455,000, "Control of immune cells: role of antiapoptosis proteins". Principal Investigator

Veterans Administration Equipment Grant, 1994, \$25,000, "Laser Confocal Microscope," Principal Investigator.

Veterans Administration Merit Review Grant, Oct 1999 - September 2003. \$471,600 "Mechanisms of Neutrophil Activation" Co-Investigator.

Federal Funding Agencies – Other:

Office of Science Financial Assistance Program-U.S. Department of Energy DE-FG02-05ER6406 PI: Jon B. Klein, M.D., Ph.D. "Clinical Proteomics Center" 2005-2010. \$3,000,000.

Department of Energy: (DAM.D.17-PC03-IDEA) May-2004 – April 2007. \$551,042 "Mechanistic Studies of oligonucleotide Aptamers with Potent Antiproliferative and Pro-apoptotic Activity against Prostate Cancer Cells."

NASA (NRS-89-OSSA), 1990 - 1994, \$258,600, "Cell biology/immunology studies aboard the international microgravity laboratory-2," Co-Investigator.

NASA-Ames (NCA2-574), 1990-1992, \$10,000, "Signal transduction in neutrophils," Collaborating Investigator.

Local and Regional Funding Agencies

Louisville Institute for Heart and Lung Disease, 1989-1990, \$20,000, "Effect of verapamil on glomerular filtration rate in orthotopic cardiac transplant recipients on cyclosporine therapy," Co-Investigator.

American Heart Association (Kentucky Affiliate), 1989-1990, \$32,000, "Effect of interferon alpha/beta on infection and rejection in the rat cardiac allograft model," Co- Investigator.

University of Louisville Bales Research Fund, \$5,500, "Use of an affinity membrane to isolate the FMLP receptor," Principal Investigator.

President's Research Initiative, Competitive Enhancement Grant, 1994, \$6,000, "Priming of immune cells by cytokines: Role of G protein synthesis", Principal Investigator.

Baxter Healthcare Corporation Extramural Grant Program, 1994-1997, \$118,215, "Neutrophil oxidative burst dysfunction in uremia," Collaborating Investigator.

Jewish Hospital Healthcare Services Foundation, 1994-1995, \$32,750, "Establishment of a Laser Confocal Microscopy Laboratory at the University of Louisville," Principal Investigator.

National Kidney Foundation (Kentucky Affiliate) 1994-1995, \$10,000, "Establishment of a Laser Confocal Microscopy Laboratory at the University of Louisville," Principal Investigator.

Jewish Hospital Foundation, Inc. \$49,943, "Neutrophil Oxidative Burst Dysfunction in Renal Transplantation", Principal Investigator.

Kentucky Science and Engineering Foundation "Novel Therapeutic Intervention for Non-Alcoholic Steatohepatitis (NASH)" \$110,000, Co-Investigator, 2002.

Kentucky Economic Development Funding Authority, "The Kentucky Proteomics Training Facility". \$1,000,000 Principal Investigator. January 01/2003 – December 2004.

Kentucky Science & Engineering Foundation International (KSEF-1034-RDE-008) – November 2005 - October 2007 \$99,853 "Proteomic Identification of Urinary Biomarkers for Diabetic Nephropathy".

Center for Genetics and Molecular Medicine (CGeMM) October 2005 – September 2006 “Proteomic analysis of diabetic nephropathy” \$15,000.

Jewish Heritage Fund for Excellence 2017-Present “Competitive Enhancement Grants” \$600,000 annually (\$1.8 million total) to support bridge grants in the Schools of Medicine, Dentistry, Nursing and Public Health and Information Sciences.

Jewish Heritage Fund for Excellence 2018-Present “Faculty Recruitment Program” \$600,000 each year (\$1.2 million total to date) to attract and retain talented faculty to the Schools of Medicine, Dentistry, Nursing and Public Health and Information Sciences.

Research Industry/Funded-Completed:

Glaxo Incorporated, 1987-1988, \$42,000, "Effect of multiple oral doses of GR32191 on cyclosporine nephrotoxicity," Principal Investigator.

Dideco Incorporated, 1987-1988, \$38,000, "Small volume therapeutic pheresis," Principal Investigator.

Genentech Incorporated, 1989, \$17,800, "Effect of parenteral interferon-gamma on PMN oxidative function," Principal Investigator.

Genentech Incorporated, 1990, \$22,000, "Effect of interferon-gamma on infection following transplantation," Principal Investigator.

Baxter International, 1994, \$22,200, "A randomized placebo controlled study to evaluate anti-CD45 monoclonal antibodies in the pretreatment of organs for the prevention of acute kidney transplant rejection", Co-principal Investigator.

Sandoz, Inc., 1993-1995, \$123,000, "A randomized multicenter three month, double-blind pharmacokinetic, safety, and tolerability study of Sandimmune Neoral soft gelatin capsules in comparison to Sandimmune soft gelatin capsules in postoperative primary renal transplants", Co-principal Investigator.

Sandoz, Inc., 1995-1998, \$171,491.80, "A multicenter randomized double blind placebo controlled trial of SDZ CHI621 for the prevention of acute cellular rejection in renal allograft recipients", Co-principal Investigator.

Genomic Solutions, Inc., \$175,000, Development of an Improved Electrophoresis Gel Support. Co-principal Investigator.

Industry:

ACTIVE – None

RESEARCH SUPPORT (Federal): ACTIVE

NIH 1-UM1-DK100865-01 (Subaward) – RINCH/Research Institute at Nationwide Children’s Hospital
Multiple PI: Jon B. Klein, M.D., Ph.D.
.60 Cal Months (5%)

10/01/2019 – 9/30/2024

“Integrative Proteomics & Metabolomics for Pediatric Glomerular Disease Biomarkers”

The immediate goal of this project is to build a biobank of 1,400 patients with five different glomerular diseases. These specimens will be used to discover and characterize plasma and urine biomarkers of pediatric glomerular disease biomarkers using mass spectrometry.

NIH 1K08DK102452-01

PI: Dawn Caster, M.D.
Mentor: Jon B. Klein, M.D., Ph.D.
0.00 calendar (0%)

02/25/2016-02/24/2021
\$761,010

“Nephritogenic autoantibodies in systemic lupus”

This mentored Career Development proposal will identify and characterize the nephritogenic autoantibodies that cause MLN using a similar experimental direction that identified PLA2R as target antigen on IMN.

1 R01 DK110077-01

Multiple PI: Jon Klein, M.D., Ph.D along with PI at Research Institute at Nationwide Children’s Hospital; William Smoyer, MD.

9/20/2016-8/31/2021
\$1,796,538

“Integrating Proteomics and Metabolomics to Understand Pediatric Glomerular Disease Pathophysiology and Prognosis”

1.2 calendar (10%)

The immediate goal of this project is to discover and characterize urine biomarkers of pediatric glomerular disease biomarkers using combined metabolomic and proteomic analysis.

PATENTS:

1. Czarniecki C, Klein JB, Slater AD, Sonnenfeld G: Control of microbial infections in transplant patients. United States Patent 5,248,499. September 28, 1993.

2. Harding G, Klein E, Klein JB: Improved Electrophoresis Gel Support. U.S. Patent Application Serial No. 60/202,264. University of Louisville File No. 91101 and 91102. August 15, 2000. U.S. Patent 6,833,060 B2 December 21, 2004
3. Klein JB, Merchant ML, Boratyn G: Peptide Biomarkers Predictive of Renal Function Decline and Kidney Disease. U.S. Provisional Patent 60/974, 002 September 20, 2007.
4. Klein JB, Merchant ML, Ouseph R, Ward RA, University of Louisville Research Foundation, Inc.: Peptide Biomarkers of Cardiovascular Disease. U.S. Provisional Patent Application 60/970, 121 & 60/970, 369. September 6, 2007. U.S. Patent 8,703,435 April 22, 2014. CIP 9,588,128 March 3, 2017
5. Klein, JB, Klein, E, Merchant, M, University of Louisville Research Foundation, Inc.: Isolation of membrane vesicles from biological fluids and methods of using same. U.S. Provisional Patent Application 60/795,063. U.S. Patent 8,758,991 9 June 24, 2014
6. Tezel, T, Kaplan, H, Klein, J, University of Louisville Research Foundation, Inc.: Hemoglobin-based methods for optimizing prophylaxis, diagnosis and/or treatment of retinal and choroidal diseases. U.S. Provisional Patent Application 60/796,224. April 26, 2006.
7. Merchant, M, Klein, J, Brier, M, Gaweda, A, University of Louisville Research Foundation, Inc.: Methods and Kits for Predicting a Response to an Erythropoietic Agent. U.S. 14/712,323 August 7, 2018.
8. Agrawahl, S, Smoyer, W, Klein, J, Merchant, M, The Research Institute at Nationwide Children's Hospital: Steroid Resistance in Nephrotic Syndrome. WO2018094021A1 November 16, 2017.

INVENTION DISCLOSURES

<u>Invention Title</u>	<u>Disclosed</u>	<u>Application</u>	<u>IP Title</u>	<u>Country</u>	<u>Filed</u>
Use of ifn-gamma for the treatment of infections in transplant recipients			Use of ifn-gamma for the treatment of infections in transplant recipients	PCT	
Improved isoelectric focusing capillary gel - microporous fibers	36467	60/202,264	Improved electrophoresis gel support	United States	5/5/00

Improved isoelectric focusing capillary gel - microporous fibers	36467	PCT/US01/14617	Improved electrophoresis gel support	PCT	5/7/01
Improved isoelectric focusing capillary gel - microporous fibers	36467	09/850,540	Electrophoresis gel support	United States	5/7/01
Improved isoelectric focusing capillary gel - polyethylene capillaries	36467				
Device and process for the separation of minute amounts of complex protein mixtures prior to analysis by instrumental or biological means	36942				
Proteomic profile of diabetic kidney disease	37141				
Facilitation of minor component identification in 2-d page gels	37179				
Selective surface adsorption media	38169				
An improved methodology for protein and peptide biomarker discovery in urine	38527				
Process for the rapid recovery of exosomes from urine and other biological fluids	38527	60/795,063	Isolation of membrane vesicles from biological fluids and methods of using same	United States	4/26/06
Process for the rapid recovery of exosomes from urine and other biological fluids	38527	PCT/US07/067509	Isolation of membrane vesicles from biological fluids and methods of using same	PCT	4/26/07

Process for the rapid recovery of exosomes from urine and other biological fluids	38527	12/298,467	Isolation of membrane vesicles from biological fluids and methods of using same	United States	10/24/08
Hemoglobin (hgb) expression in human retinal pigment epithelium (rpe): a new perspective on oxygen transport to the outer retina	38778	60/796,224	Hemoglobin-based methods for optimizing prophylaxis, diagnosis and/or treatment of retinal and choroidal diseases	United States	4/28/06
Hemoglobin (hgb) expression in human retinal pigment epithelium (rpe): a new perspective on oxygen transport to the outer retina	38778	PCT/US07/64940	Hemoglobin (hgb) expression in human retinal pigment epithelium (rpe): a new perspective on oxygen transport to the outer retina	PCT	3/26/07
Hemoglobin (hgb) expression in human retinal pigment epithelium (rpe): a new perspective on oxygen transport to the outer retina	38778	60/785,884	Hemoglobin based methods for optimizing prophylaxis, diagnosis and/or treatment of retinal and choroidal diseases	United States	3/24/06
Hemoglobin (hgb) expression in human retinal pigment epithelium (rpe): a new perspective on oxygen transport to the outer retina	38778	12/294,409	Hemoglobin-based methods for prophylaxis, diagnosis and/or treatment of retinal disorders	United States	9/24/08
Hemoglobin (hgb) expression in human retinal pigment epithelium (rpe): a new perspective on oxygen transport to the outer retina	38778	2007230570	Hemoglobin-based methods for prophylaxis, diagnosis and/or treatment of retinal disorders	Australia	10/16/08

Hemoglobin (hgb) expression in human retinal pigment epithelium (rpe): a new perspective on oxygen transport to the outer retina	38778	7759392.9	Hemoglobin-based methods for prophylaxis, diagnosis and/or treatment of retinal disorders	Europe	12/24/08
Novel window-based normalization procedure for comparative analysis of mass spectra	38784				
Specific phosphorylated peptide biomarkers of coronary artery disease	38940	60/913,069	Peptide biomarkers of cardiovascular disease	United States	4/20/07
Specific phosphorylated peptide biomarkers of coronary artery disease	38940	60/970,369	Peptide biomarkers of cardiovascular disease	United States	9/6/07
Specific phosphorylated peptide biomarkers of coronary artery disease	38940	60/970,121	Peptide biomarkers of cardiovascular disease	United States	9/5/07
Specific phosphorylated peptide biomarkers of coronary artery disease	38940	PCT/US08/60879	Peptide biomarkers of cardiovascular disease	PCT	4/18/08
Specific phosphorylated peptide biomarkers of coronary artery disease	38940	12/596,814	Peptide biomarkers of cardiovascular disease	United States	10/20/09
An improved biomarker of coronary artery disease	38940				
A method and apparatus for real-time baseline removal and peak detection in mass spectra	38960				

Biomarkers to identify and predict renal function decline in diabetes mellitus	39072	60/974,002	Peptide biomarkers predictive of renal function decline and kidney disease	United States	9/20/07
Biomarkers to identify and predict renal function decline in diabetes mellitus	39072	61/050,521	Peptide biomarkers predictive of renal function decline and kidney disease	United States	5/5/08
Biomarkers to identify and predict renal function decline in diabetes mellitus	39072	PCT/US08/77091	Peptide biomarkers predictive of renal function decline and kidney disease	PCT	9/19/08
Biomarkers to identify and predict renal function decline in diabetes mellitus	39072	12/234,401	Peptide biomarkers predictive of renal function decline and kidney disease	United States	9/19/08
Biomarkers to identify and predict renal function decline in diabetes mellitus	39072	8832096.5	Peptide biomarkers predictive of renal function decline and kidney disease	Europe	4/20/10
Urinary and plasma peptidyl biomarkers of cervical dysplasia and cervical cancer	39512				
Plasma biomarkers of early progressive renal function decline	39512				
Urinary exosomes as a source for diagnostic micro RNA biomarkers	39934				

Single-step rapid isolation of microparticles and microvesicles from biological fluids and cell culture material for clinical assay purposes	39944			
Urinary biomarkers of idiopathic membranous nephropathy and renal function decline	40134			
Urinary exosomal biomarkers of nephrotic disease	40134			
Biomarkers of response to erythropoietic stimulating agents in dialysis patients and anemia of chronic disease	40287	61/357,843	Methods and kits for predicting a response to an erythropoietic agent	United States

EDITORIAL BOARDS AND MANUSCRIPT REVIEW

Co-Editor, International Journal of Artificial Organs 2008-2014

Member, Editorial Board, Clinical Nephrology 1991-Present

Member, Editorial Board, Journal of Cardiovascular Toxicology 2001-2007

Reviewer, The Journal of Clinical Investigation

Reviewer, The New England Journal of Medicine

Reviewer, Nature - Medicine

Reviewer, Journal of Immunology

Reviewer, Journal of Neuroscience

Reviewer, Kidney International

Reviewer, Journal of the American Society of Nephrology

Reviewer, Journal of Interferon Research

Reviewer, The American Journal of the Medical Sciences

ABSTRACTS

1. **Klein JB**, Kyner J: Hyperchloremic non-gap acidosis following recovery from diabetic ketoacidosis. Presented at the Kansas State Meeting of the American College of Physicians, April 1980.
2. **Klein JB**, McLeish K, Hodsden J, Lordon R: Hypertrophic cardiomyopathy: An acquired disorder of end stage renal disease. ASAIO Abstracts 12:53, 1983. Presented at the American Society for Artificial Internal Organs, April 28-30, 1983.
3. Klein LR, **Klein JB**, Hanno R, Callen JP: Mast cell quantity in pruritus of hemodialysis. Clinical Research, April 1986.

4. **Klein JB**, Gondi B, McLeish KR, Wathen RL: Comparison of acetate and bicarbonate dialysis in patients with concentric ventricular hypertrophy. Presented at the American Society of Nephrology, December 1985. *Kidney International* 29:217, 1986.
5. Gray LA, Slater AD, **Klein JB**, Davis MH: A successful cardiac transplantation program using combined university and community resources. Presented at the Southern Surgical Association, Palm Beach, Florida, November 30, 1986.
6. Salières R, Pfeiffer M, Tamburro C, **Klein J**, Fogel R: Abnormal parasympathetic activity in alcoholic cirrhosis. American Gastroenterological Association, May 10-13, 1987. *Gastroenterology* 92:1770, 1987.
7. **Klein JB**, Wellhausen SR, Murchison KE, Gray LA, Chang BS, Bunke CM, McLeish KR: Flow cytometric analysis of the monocyte cell cycle as an aid in the diagnosis of cardiac graft rejection. Presented at the American Society of Transplant Physicians, Chicago, Illinois, May 1987.
8. Callen JP, **Klein JB**: Complement component C2 deficiency among patients with subacute cutaneous lupus erythematosus. Presented at the American Rheumatism Association, June 9-13, 1987.
9. **Klein JB**, Bunke CM, Chang BS, Brohm JA, McLeish KR, Gray LA: Sustained periods without rejection following treatment of cardiac allograft recipients with OKTR3. Presented at the International Organ Transplant Forum, September 8-11, 1987.
10. **Klein JB**, McLeish KR, Sonnenfeld G: Alterations of membrane potential in U937 cells induced by interferon- γ . Presented at the International Society for Interferon Research on the Interferon System, November 2-6, 1987.
11. **Klein JB**, McLeish KR, Dean WL, Sonnenfeld G: Effect of interferon- γ on the intracellular calcium concentration of U937 cells. Presented at the International Society for Interferon Research on the Interferon System, November 2-6, 1987.
12. Callen JP, **Klein JB**: Subacute cutaneous lupus erythematosus: Clinical, serologic, immunogenetic and therapeutic considerations in 72 patients. Presented at the American Rheumatism Association Central Meeting, Chicago, Illinois, November 13, 1987.
13. **Klein J**, Dean W, Sonnenfeld G, McLeish K: Intracellular calcium redistribution in interferon stimulated expression of histocompatibility antigens. Presented at the National American Federation for Clinical Research, Washington, D.C., April 30, 1988. *Clinical Research* 36:442A, 1988.
14. **Klein J**, Wellhausen S, Dean W, McLeish K: Intracellular calcium redistribution as a necessary signal in the priming of neutrophils by lipopolysaccharide. Presented at the National American Federation for Clinical Research, Washington, D.C., May 1, 1988. *Clinical Research* 36:442A, 1988.

15. **Klein J**, Catapano G, Feldhoff P, Bunke C, Klein E: Small volume therapeutic pheresis as an alternative to conventional pheresis. Presented at the World Apheresis Association 2nd International Congress, Ottawa, Canada, May 18, 1988.
16. Sloan R, Bunke C, Mudd L, **Klein J**: Volume homeostasis after small volume pheresis. Presented at the World Apheresis Association 2nd International Congress, Ottawa, Canada, May 18-19, 1988.
17. Tanner MK, Wellhausen SR, **Klein JB**: Cyclosporine a induced hyperpolarization of monocyte membranes. Presented at the Society for Analytical Cytology, 1988.
18. **Klein JB**, McLeish KR, Dean WL, Sonnenfeld G: Utilization of multiple signal transduction pathways by interferon-gamma in the induction of surface antigens on U937 cells. Presented at the International Society for Interferon Research, Kyoto, Japan, November 17-21, 1988.
19. **Klein JB**, Dean WL, Sonnenfeld G, McLeish KR: The role of protein synthesis in the induction of surface antigens on U937 cells by interferon-gamma. Presented at the International Society for Interferon Research, Kyoto, Japan, November 17-21, 1988.
20. **Klein J**, Sonnenfeld G, Dean W, McLeish KR: Signal transduction pathways used by interferon-gamma to induce surface antigens on U937 cells. *Clinical Research* 36:843A, 1988.
21. **Klein JB**, Dean W, Sonnenfeld G, McLeish KR: The role of protein synthesis in the induction by interferon-gamma of surface antigens on U937 cells. *Clinical Research* 36:843A, 1988.
22. Schepers TM, Feldhoff PA, Dean WL, **Klein JB**, McLeish KR: Interferon- γ stimulated protein phosphorylation in U937 cells differs from that stimulated by ionomycin or phorbol diesters. *The FASEB J* 3:1290A, 1989. Presented at the FASEB, March 19-23, 1989.
23. **Klein J**, Baty L, Sonnenfeld G, McLeish K: Interferon- γ and tumor necrosis factor enhance FMLP-induced superoxide production by HL-60 cells. *The FASEB J* 3:634A, 1989. Presented at the FASEB, March 19-23, 1989.
24. **Klein J**, Schepers T, Sonnenfeld G, Dean W, Feldhoff P, McLeish K: Intracellular calcium, but not protein kinase C activation, is necessary for interferon-gamma induction of HLA-DR on U937 cells. *Kidney Int* 35:175A, 1989. Presented at the American Society of Nephrology, San Antonio, TX, December 1988.
25. Schepers TM, Feldhoff PA, Dean WL, **Klein JB**, McLeish KR: Interferon-activates a calcium-dependent protein kinase which is neither protein kinase C nor a calcium-calmodulin dependent kinase. *J Interferon Res (Suppl 2)*:S96, 1989. Presented at the 1989 Annual Meeting of the ISIR, Florence, Italy, October 1989.
26. McLeish KR, Schepers T, Beck M, Eades S, **Klein JB**, Sonnenfeld G: Tumor necrosis factor- α -induced increase in formyl peptide receptors results in an increase in G protein activation but not in second messenger generation. *J Interferon Res* 9(Suppl 2):S247, October 1989. Presented at the 1989 Annual Meeting of the ISIR, Florence, Italy, 1989.

27. **Klein JB**, McLeish K: Disparate superoxide production to formyl peptides and LTB4 are not due to differences in the duration of calcium transients. Submitted to American Federation for Clinical Research, January 1990.
28. Golper TA, Jenkins R, Wright M, **Klein JB**. Tumor necrosis factor (TNF) and hemofiltration membranes. Submitted to IInd International Conference on Continuous Hemofiltration, April 1990.
29. Wright M, Harding GB, Klein E, **Klein JB**. Neutrophil activation by contaminated dialysate. Presented at the XXVIIth Congress of the European Dialysis and Transplant Association - European Renal Association, Vienna, Austria, September 5-9, 1990.
30. **Klein JB**, Scherzer JA, McLeish KR: Modulation of transmembrane signalling by interferon- γ . Presented at the International Society for Interferon Research, San Francisco, California, November 14-18, 1990.
31. Meckler G, **Klein JB**, McLeish KR: Magnesium regulation of G protein affinity for guanine nucleotides. *JASN* 1(4):476, 1990. Submitted to American Society of Nephrology, Washington, D.C., December 2-5, 1990.
32. **Klein JB**, Scherzer JA, McLeish KR: Interferon- γ enhances transmembrane signalling in HL-60 cells. *JASN* 1(4):529, 1990. Presented at the American Society of Nephrology, Washington, D.C., December 2-5, 1990.
33. Wright M, Harding GB, Klein E, **Klein JB**. Activation of monocytes by contaminated dialysate. *JASN* 1(4):382, 1990. Presented at the American Society of Nephrology, Washington, D.C., December 2-5, 1990.
34. Erbeck K, **Klein JB**, Scherzer J, McLeish K: Differential uncoupling of chemoattractant receptors from G proteins in retinoic acid-differentiated HL-60 granulocytes. Presented to the American Society of Nephrology, Baltimore, Maryland, November 17-20, 1991.
35. Wright M, Klein E, **Klein JB**. Passage of bacterial contents across dialyzers that stimulate tumor necrosis factor (TNF) release. Presented to the American Society of Nephrology, Baltimore, Maryland, November 17-20, 1991.
36. Erbeck K, **Klein JB**, McLeish K: Impaired ADP-ribosylation of G proteins in retinoic acid-differentiated HL-60 granulocytes. Presented to the American Federation for Clinical Research, Baltimore, Maryland, May 1-4, 1992. *Clin Res* 40(2):224A, 1992.
37. **Klein JB**, Scherzer J, McLeish K: Rapid modulation of neutrophil transmembrane signaling by tumor necrosis factor- α . Presented to the American Federation for Clinical Research, Baltimore, Maryland, May 1-4, 1992. *Clin Res* 40(2):241A, 1992.
38. Bunke M, Ganzel B, **Klein JB**, Oldfather J: Effect of positive B cell crossmatch on rejection in cardiac transplant recipients. Presented to the American Society of Transplant Physicians, Chicago, Illinois, May 26-27, 1992.

39. **Klein JB**, Scherzer JA, McLeish KR: Tumor necrosis factor- α rapidly modulates G protein expression in polymorphonuclear leukocytes. Presented to the Central Society for Clinical Research, Chicago, Illinois, November 4-6, 1992 and the American Society of Nephrology, Baltimore, Maryland, November 15-18, 1992. Clin Res 40(3):745A, 1992. JASN 3(3):498, 1992.
40. **Klein JB**, Scherzer J: Tumor necrosis factor- α increases G protein expression in polymorphonuclear leukocytes by both translocation and synthesis of G proteins. Presented to the American Federation For Clinical Research, Washington, DC, April 30-May 3, 1993.
41. McLeish KR, Lederer ED, **Klein JB**. Inhibition of isoprenylation alters expression of transmembrane signaling components. JASN 4:494, 1993.
42. McLeish KR, Lederer ED, **Klein JB**, Hoffman JL: Prenylcysteine analog inhibition of receptor-mediated G protein activation. Role of carboxymethylation. JASN 4:494, 1993.
43. McLeish KR, **Klein JB**, Ward RA: Neutrophils from azotemic patients have increased guanine nucleotide regulatory protein activity. Presented to the American Society of Nephrology, Orlando, Florida, October 25-29, 1994. JASN 5:950, 1994.
44. Brier, ME, Bentley FR, **Klein JB**. Choice of therapy prediction using an artificial neural network. Clinical Res. 43(3):478A, 1995.
45. **Klein JB**, Bentley FR, Brier ME: Correlation of HLA-DR and race mismatch with delayed renal allograft function. Clinical Res. 43(3)488A, 1995.
46. **Klein JB**, Ward RA, Lederer ED, McLeish KR: Azotemic neutrophils show increased basal guanine nucleotide exchange by multiple GTP binding proteins. Clinical Res. 43(3):471A, 1995.
47. Pescovitz M, Barone G, Wombolt D, Pruett T, Stinson J, Min D, Thompson J, **Klein JB**, Marsh C, Pollak R, Vasquez E, Choc MG, Wong RL, Jin J. Pharmacokinetic/Pharmacodynamic correlations with rejection episodes using a new oral formulation of cyclosporine (NeoralTM) in de novo renal transplant patients. American Society of Transplant Physicians 139, May 14-16, 1995.
48. Pescovitz M, Barone G, Wombolt D, Pruett T, Stinson J, Min D, Thompson J, **Klein JB**, Marsh C, Pollak R, Vasquez E, Hricik D, Choc MG, Jin J, Wong RL. Comparison of safety and tolerability in de novo renal transplant patients treated with SandimmuneR and NeoralTM. American Society of Transplant Surgeons. May 17-19, 1995.
49. Scherzer J, McLeish K, **Klein JB**: TNF induced regulation of G α i2 protein and mRNA expression in polymorphonuclear leukocytes. Presented at the American Federation for Clinical Research (Midwest Section).
50. Brier M, Bentley F, **Klein JB**: Predicting primary non-function of renal allografts using neural networks. Presented at the American Federation for Clinical Research.
51. Ward RA, **Klein JB**, Lederer ED, McLeish KR: Azotemic neutrophils show increased basal guanine nucleotide exchange by multiple GTP binding proteins. Presented at the American Society of Nephrology.

52. Pruett T, Wombolt D, Pollak R, Vasquez E, Barone G, Bunke C, **Klein JB**, Pescovitz M, Thompson J, Waid T, Marsh C, Stinson J, Choc M, Chang CT, Wong R. Comparison of cyclosporine bioavailability with NeoralR (Neoral) and SandimmuneR in black de novo renal transplant patients. American Society of Transplant Physicians. Dallas, TX May 27-31, 1996.
53. Pescovitz M.D., Stinson J, Wombolt D, **Klein JB**, Barone G, Pruett TL, Min D, Thompson J, Waid T, Marsh C, Pollak R, Vasquez E, Hricik D, Choc MG, Jin J, Hwang DS, Wong RL. Safety and tolerability of NeoralR (Neoral) vs. SandimmuneR: two year data in primary renal allograft patients. American Society of Transplant Physicians. Dallas, TX May 27-31, 1996.
54. Ward BA, **Klein JB**, McLeish KR. The Oxidative Burst Response of Neutrophils (PMNs) and HL-60 Granulocytes is Primed by Exposure to Plasma from Patients with Azotemia. Presented at the American Society of Nephrology, New Orleans, Nov. 3-6, 1996. 7(9):1867
55. Lin Y, Davis SC, McLeish KR, Rane MJ, Scherzer JA, **Klein JB**. Tumor Necrosis Factor- α Up-regulation of Gai2, Gene Expression in Human Neutrophils is Mediated by the EGR-1 Transcription Factor. Presented at the American Society of Nephrology, New Orleans, Nov. 3-6, 1996. 7(9):1681
56. Lederer ED, Mathiesen J, **Klein JB**. Inhibition of NaPi-4 Expression by Parathyroid Hormone (PTH), 8-Bromo-cAMP (8Br) and Phorbol Myristate Acetate (PMA). Presented at the American Society of Nephrology, New Orleans, Nov 3-6, 1996. 7(9):1803
57. McLeish KR, Ward RA, **Klein JB**, Johnson GL. Role of Mark Activation in the TNF α Priming of Polymorphonuclear Leukocytes (PMNs). Presented at the American Society of Nephrology, New Orleans, Nov. 3-6, 1996. 7(9):1682
58. Carrithers S, Rane M., Eades S., **Klein JB**, McLeish KR. Formyl Peptide Receptors Activate Multiple Mitogen-Activated Protein Kinase (MAPK) Pathways. Presented at the American Society of Nephrology, New Orleans, Nov. 3-6, 1996. 7(9):2124
59. Lin, Y, Davis, SC, McLeish, KR, Rane, MJ, Scherzer, JA, and **Klein JB**. Tumor necrosis factor up-regulation of G i2 gene expression in human neutrophils is mediated by EGR-1 transcription factor. JASN 7:1681, 1996. Presented at the 1996 American Society of Nephrology.
60. Ward, RA, McLeish, KR, **Klein JB**. Priming of neutrophil (PMN) oxidative burst activity by azotemia is not corrected by high-efficiency hemodialysis (HEHD) or CAPD. JASN: 8; 1997 1998
61. Rane, MJ, Arthur, JM, **Klein JB**, McLeish, KR. The cytoplasmic tail of the formly peptide receptor (FPR) regulates ligand-stimulated MAPK activation. JASN: 8;1997 1998
62. Davis, SC, Scherzer, JA, Mathieson, JA, McLeish, KR, **Klein JB**. Identification of a novel gene by differential display PCR in TNF α -stimulated human neutrophils (PMNs). JASN: 8; 1997 1998
63. Li,Y, Davis, SC, Mathieson, JA, McLeish, KR, **Klein JB**. Regulation of human neutrophil G α 2 Transcription by bacterial lipopolysaccharide. JASN 8; 1997 1998

64. Kettritz R, Xu Y, Faass B, Muller EC, Otto A, **Klein JB**, Luft FC, Haller H: Identification of regulatory proteins in apoptosis of human neutrophils. *JASN* 9:A2446, 1998.
65. Kettritz R, Xu Y, Faass B, Muller EC, Otto A, **Klein JB**, Luft FC, Haller H: Acceleration of TNF α -mediated neutrophil-apoptosis on extracellular matrix is associated with increased phosphorylation and cleavage of LY-GDI, a regulator of RHO GTPases. *JASN* 9:A2447, 1998.
66. **Klein JB**, Scherzer JA, Mathiesen JM, Haller H, McLeish KR, Kettritz R: Role of MAPK in GM-CSF inhibition of human neutrophil (PMN) apoptosis. *JASN* 9:A2449, 1998.
67. McLeish KR, Coxon PY, Rane MJ, Manning T: Participation of MAPKs in disparate regulation of neutrophil apoptosis by chemoattractants. *JASN* 9:A2460, 1998.
68. **J Klein**, G-W Wang, Z Zhou, A Buridi, Y J Kang: TNF- α stimulates cardiomyocyte apoptosis by A p38 MAPK-dependent pathway requiring reactive oxygen species. Presented at the Society of Toxicology, 39th Annual Meeting: 2000
69. Wang GW, Zhou Z, **Klein JB**, Kang YJ. Inhibition of Apoptosis by Hypoxia/reoxygenation in Mt-Overexpressing Cardiomyocytes. Presented to The Oxygen Society, March, 2000
70. Pescovitz M.D., Barone G, Choc MG, Hricik DE, Hwang DS, Jin JHJ, **Klein JB**, Marsh CL, Min DI, Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasque E, Waid T, Wombolt DG, Wong RL. Safety and Tolerability of Cyclosporine Microemulsion vs. Cyclosporine: 2- Year Data in Primary Renal Allograft Recipients. Submitted to the American Society of Transplant Physicians. 2000
71. Pollak R, Vasquez E, Pruett TL, Pescovitz M.D., Wombolt D, Barone G, Bunke C, **Klein JB**, Thompson JS, Waid T, Marsh CL, Min DI, Stinson JB, Choc MG, Wong RL, Chang CT. Cyclosporine Bioavailability of Neoral and Sandimmune in White and Black De Novo Renal Transplant Recipients. Submitted to The American Society of Transplant Physicians. 2000
72. Gozal,E, **Klein,JB**, Pierce, WM, Scherzer, JA, Cai, J, Sachleben, LR. Proteomic analysis of CA1 and CA3 regions of hippocampus following 6 hours of intermittent hypoxia. Presented at the Society for Neuroscience annual meeting . April, 2000
73. Rane, MJ, Coxon, PY, Powell, DW, **Klein, JB**, McLeish, KR. Akt Activation in human neutrophils is mediated by a signal complex which includes p38 MAP kinase, MK2, and HSP27. Presented at the ASBMB/ASPET Joint Meeting 2000: 1530
74. Thongboonkerd V, McLeish KR, Arthur JM, **Klein JB**. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation. *JASN* 13:119A, 2002.
75. Thongboonkerd V, **Klein JB**, McLeish KR. Proteomic identification of biomarkers for glomerular diseases. *JASN* 13:120A, 2002.
76. Thongboonkerd V, **Klein JB**, McLeish KR. Proteomic analysis of hypoinsulinemic diabetic nephropathy. *JASN* 13:120A, 2002.

77. Hina Kausar, Evelyne Gozal, Rui Wu, Diego Montoya-Durango, **Jon B. Klein**, Madhavi J. Rane. Hsp27 Acts as a Scaffolding Protein for Upstream Activators of Akt. [F-PO146] American Society of Nephrology 2004 Renal Week
78. M. T. Barati, M. J. Rane, **J. B. Klein**, K. R. McLeish. Akt Phosphorylates Stress-Induced Chaperone Proteins in Rat Mesangial Cells. [F-PO152] American Society of Nephrology 2004 Renal Week
79. James Gould, Madhavi Rane, Rui Wu, **Jon Klein**. Role of Akt in the Production of TGF β . [F-PO166] American Society of Nephrology 2004 Renal Week
80. Patrick K. Leong, Li E. Yang, Angela Devillez, **Jon B. Klein**, Alicia A. McDonough. Proximal Tubule NHE3 Is Retracted from the Microvilli during Captopril Treatment and Restored to Microvilli by Acute Angiotensin II Infusion. [F-PO588] American Society of Nephrology 2004 Renal Week
81. Madhavi J. Rane, Rui Wu, Hina Kausar, Leroy R. Sachleben, Jr., **Jon B. Klein**, Evelyne Gozal. Akt Autophosphorylation Inhibits Hypoxia Induced Akt Ser473 Phosphorylation and Regulates HK-11 Cell Survival. [SA-PO683] American Society of Nephrology 2004 Renal Week
82. Michelle T. Barati, Angela B. DeVillez, Kenneth R. McLeish, **Jon B. Klein**. Altered Cellular Redox Pathways and Advanced Glycation End Product (AGE) Metabolism in Glomeruli of db/db Diabetic Mice Defined by Proteomic Analysis. [SA-PO748] American Society of Nephrology 2004 Renal Week
83. Rui Wu, Evelyne Gozal, Michelle T. Barati, Leroy R. Sachleben, Jr., **Jon B. Klein**, Madhavi J. Rane. Akt Phosphorylation of Nuclear Factor-Erythroid 2 (NF-E2) Regulates NF-E2 DNA Binding Activity in Neutrophils (PMNs). [SA-PO913] American Society of Nephrology 2004 Renal Week
84. Eleanor D. Lederer, Angela Devillez, Reeta S. Tyagi, John A. Nesbitt, **Jon B. Klein**. Proteomic Analysis of Urine from Patients with Calcium Oxalate Kidney Stones. [SA-PO997] American Society of Nephrology 2004 Renal Week
85. Richard F. Ransom, Virginia Vega-Warner, Jon Klein, William E. Smoyer. Increased Hsp27 Expression Mimics the Protection from Injury and Actin Filament Disruption Conferred by Dexamethasone. [SU-PO003] American Society of Nephrology 2004 Renal Week
86. Michael L. Merchant, Michelle T. Barati, William M. Pierce, **Jon B. Klein**. Rat Mesangial Cell Line Proteome Map. [SU-PO620] American Society of Nephrology 2004 Renal Week
87. Mary Jayne Kennedy, Michael Merchant, Angela Griffin, Angela DeVillez, **Jon Klein**. Urinary Proteomic Profiling Identifies Candidate Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Children. [F-FC035] American Society of Nephrology 2005 Renal Week
88. Madhavi J. Rane, Michelle T. Barati, David Gozal, Rui Wu, Leroy R. Sachleben, Evelyne Gozal, **Jon B. Klein**. Phosphorylation of VCP Regulates Its Association with Ubiquitinated Proteins: Identification of Akt Phosphorylation Sites. [F-PO164] American Society of Nephrology 2005 Renal Week

89. Michelle T. Barati, Michael L. Merchant, Kenneth R. McLeish, **Jon B. Klein**. Analysis of Glyoxalase I Activity in Renal Cortex of db/db Diabetic Mice. {F-PO312} American Society of Nephrology 2005 Renal Week
90. Michael L. Merchant, Mary Jane Kennedy, Elias Klein, **Jon B. Klein**. Biomarker Discovery in Urine through Direct Mass Spectrometric Determination of Endogenous Low Molecular Weight Peptides. [TH-PO163] American Society of Nephrology 2005 Renal Week
91. Michael L. Merchant, James C. Gould, Michelle T. Barati, Daniel W. Wilkey, **Jon B. Klein**. [TH-Elevated Glucose Stimulates Coordinated Changes in Transcriptional, Translational and Chaperone Protein Expression in Mesangial Cells. [TH-PO382] American Society of Nephrology 2005 Renal Week
92. Eleanor D. Lederer, Michael L. Merchant, Angie Kain, **Jon B. Klein**. Urinary Proteomic Analysis Reveals Differential Patterns in Calcium and Uric Acid Stone Formers. [TH-PO883] American Society of Nephrology 2005 Renal Week.
93. Michael L. Merchant, Grzegorz M. Boratyn, Bruce A. Perkins, Grier P. Page, Linda H. Ficociello, Daniel W. Wilkey, James H. Warram, Andzrej S. Krolewski, **Jon B. Klein**. Urinary Peptidomic Analysis Demonstrates Changes in Extracellular Matrix Protein Excretion in Patients with Microalbuminuria and Early Progressive Renal Function Decline. [F-FC078] American Society of Nephrology 2007 Renal Week.
94. Michael L. Merchant, Daniel W. Wilkey, Timothy D. Cummins, Sarah A. Salyer, **Jon B. Klein**, Eleanor D. Lederer. Proteomic Analysis of Renal Calculi Matrix Proteins Using a High-Sensitivity LC-MS/MS Approach. [SA-PO121] American Society of Nephrology 2007 Renal Week.
95. Michael L. Merchant, Grier P. Page, Bruce A. Perkins, Linda H. Ficociello, Grzegorz M. Boratyn, Daniel W. Wilkey, James H. Warram, Andzrej S. Krolewski, **Jon B. Klein**. Candidate Plasma Peptide Biomarkers Discriminate Progression or Non-Progression of Renal Functional Decline in Microalbuminuric Type-1 Diabetics. [SA-PO122] American Society of Nephrology 2007 Renal Week.
96. Mary Jayne Kennedy, Angela Griffin, Michael Merchant, **Jon Klein**. Urine Collected from Non-Gel Containing Diapers Can Be Used for Proteomic Profiling in Infants and Young Children. [SA-PO127] American Society of Nephrology 2007 Renal Week.
97. Janice A. Scherzer, Linda H. Ficociello, Bruce A. Perkins, Daniel W. Wilkey, Grzegorz M. Boratyn, Michael L. Merchant, James H. Warram, **Jon B. Klein**, Andzrej S. Krolewski Difference In-Gel Electrophoresis Analysis of the Urinary Proteome in Patients with Type 1 Diabetes and New Onset Microalbuminuria According to Presence and Absence of Renal Function Decline. [SA-PO140] American Society of Nephrology 2007 Renal Week.
98. Timothy D. Cummins, Clinton C. Bertram, **Jon B. Klein**, David W. Powell. Quantitative Comparison of Renal Tubular Proteomes in OVE26 Diabetic and Control Mice by Liquid Chromatography Coupled Mass Spectrometry. [SA-PO245] American Society of Nephrology 2007 Renal Week.

99. Laurence H. Beck, Ramon G. B. Bonegio, Eric W. Eisenberg, David W. Powell, Timothy D. Cummins, **Jon B. Klein**, David J. Salant. Towards the Identification of the Autoantigen in Membranous Nephropathy. [SA-PO401] American Society of Nephrology 2007 Renal Week.
100. Michelle T. Barati, Madhavi J. Rane, **Jon B. Klein**. Albumin-Induced Endoplasmic Reticulum Stress in Human Proximal Tubule Cells Is Mediated by Reactive Oxygen Species. [SU-PO158] American Society of Nephrology 2007 Renal Week.
101. Madhavi Rane, Michelle Barati, Betty Villafuerte, Rui Wu, Hina Kausar, Jon Klein. C-Terminal Tail of the GABAB Receptor Acts as a Transcription Regulator in Human Renal Proximal Tubular Cells (RPTCs) Via an Akt-Dependent Signaling Pathway. [SU-PO185] American Society of Nephrology 2007 Renal Week.
102. David W. Powell, Clinton C. Bertram, Timothy D. Cummins, Michelle Barati, Shirong Zheng, Paul N. Epstein, **Jon B. Klein**. Tubular Epithelial-to-Mesenchymal Transition in OVE26 Diabetic Mice. [SU-P0316] American Society of Nephrology 2007 Renal Week.
103. Michelle T. Barati, David W. Powell, Shirong Zheng, Paul N. Epstein, **Jon B. Klein**. Endoplasmic Reticulum Stress in Tubules of Diabetic Mice. [SU-PO324] American Society of Nephrology 2007 Renal Week.
104. Proteomic Analysis Reveals elongin C as a Possible Mediator of Notch-4 Activity in renal Tubule Cells. Michael D. Mendenhall, Michelle T. Barati, Timothy D. Cummins, **Jon B. Klein**, David W. Powell [SA-FC365] American Society of Nephrology 2008 Renal Week.
105. Urinary Peptidomic Analysis Suggest Proximal Tubule Stress in Type-1 Diabetic Patients with Microalbuminuria Correlates with Early Progressive Renal Function Decline: Michael D. Mendenhall, Bruce A. Perkins, Grier P Page, Linda H. Ficociello, Brad H. Roven, James H. Warram, Andrzej S. Krolewski, **Jon B. Klein** [SA-FC368]. American Society of Nephrology 2008 Renal Week.
106. Glomerular Oxidant Expression alters the Urinary Peptidome in Murine Diabetic Nephropathy. Andrew J. Dailey, Michael L. Merchant, Daniel W. Wilkey, Shirong Zheng, Paul N. Epstein, **Jon B. Klein**. [SA-FC369] American Society of Nephrology 2008 Renal Week.
107. Discovery of the Phospholipase A2 Receptor as the Target Antigen in Idiopathic Membranous Nephropathy. Laurence Beck, Ramon Bonegio, Gerald Lambeau, David Powell, Timothy Cummins, **Jon Klein** [SA-FC458]. American Society of Nephrology 2008 Renal Week.
108. Identification of a New Adaptor Molecular Involved in TGF- β Signaling in Renal Tubule Epithelial Cells. Timothy D. Cummins, Clinton C. Bertram, **Jon B. Klein**, David W. Powell [F-PO1325] American Society of Nephrology 2008 Renal Week.
109. Reduced Ubiquitination of Urine Protein in Aminoglycoside-Treated Children with Nephrotoxicity. Mary Jayne Kennedy, Michael Merchant, **Jon Klein** [F-PO2021]. American Society of Nephrology 2008 Renal Week.

110. Differential Scanning Calorimetric Analysis of Plasma for Microalbuminuric Type 1 Diabetics Distinguishes Early Progressive Renal Function Decline from Stable Renal Function. Michael L. Merchant, Nichola C. Garbett, Bruce A. Perkins, James H. Warram, Andrzej S. Krolewski, Jonathan B. Chaires, **Jon B. Klein** [SAPO2176] American Society of Nephrology 2008 Renal Week.
111. Plasma Kininogen and Kininogen Peptide Fragment Levels Correlate with Progressive Renal Function Decline in Microalbuminuric Type-1 Diabetics. Michael L. Merchant, Janice Scherzer, Daniel W. Wilkey, Grier P. Page, Linda H. Ficociello, Bruce A. Perkins, James H. Warram, Andrzej S. Krolewski, **Jon B. Klein**. [SA-{P2177} American Society of Nephrology 2008 Renal Week.
112. Endoplasmic Reticulum Stress Signaling as a Mechanism of Renal Tubular Injury in Diabetes. Michelle Barati, David Powell, Paul Epstein, Madhavi Rane, **Jon Klein**. [SA-PO2372] American Society of Nephrology 2008 Renal Week.
113. Identification of Biomarkers in Nephrotic Syndrome: Isolation of Urinary Exosomes Jeroen Deegens, Ilse Rood, Micheal Merchant, Daniel Wilkey, Jack Wetzels, **Jon Klein**. [TH-PO205] American Society of Nephrology 2009 Renal Week.
114. Role and Regulation of Notch4 in TGF-beta Activity in Renal Tubules. David W. Powell, Michael D. Mendenhall, Timothy D. Cummins, Syed J. Khundmiri, Sarah A. Salyer, **Jon B. Klein**. [TH-PO724] American Society of Nephrology 2009 Renal Week.
115. Hyperglycemia Alters Kinin Signaling through the Bradykinin-2 Receptor in Cultured Renal Proximal Tubular Cells. Michael Merchant, Syed Khundmiri, Michelle Barati, David Powell, Kevin Wang, Daniel Wilkey, **Jon Klein** [TH-PO764] American Society of Nephrology 2009 Renal Week.
116. Identification of Diabetes-Induced ER Stress Response Signaling Effectors in Renal Tubule Cells Michelle T. Barati, David W. Powell, Angela Kain, Daniel Wilkey, Michael L. Merchant, **Jon B. Klein** [TH-PO778] American Society of Nephrology 2009 Renal Week.
117. Novel Proteomics Approaches to Discover Biomarkers for Predicting Prognosis in Membranous Nephropathy. Jeroen Deegens, Michael Merchant, David Powell, Timothy Cummings, Daniel Wilkey, Jack Wetzels, Jon Klein [SA-PO2289] American Society of Nephrology 2009 Renal Week.
118. Microarray Expression Profiling of miRNA in Human Urinary Exosomes. Michael Merchant, Tariq Hamid, Jeroen Deegens, Ilse M. Rood, Jack F. Wetzels, Sumanth D. Prabhu, **Jon B. Klein** [SA-PO2377] American Society of Nephrology 2009 Renal Week.
119. Proteomic Analysis of Serum from Erythropoietin Sensitive and Erythropoietin Resistant Hemodialysis Patients. Andrew J. Dailey, Michael L. Merchant, Adam E. Gaweda, Daniel W. Wilkey, Michael E. Brier, **Jon B. Klein** [SA-PO2382] American Society of Nephrology 2009 Renal Week.
120. Altered Wnt/ β -catenin Pathway and Association of β -catenin with CHOP in Tubules of Diabetic Mice. Michelle T. Barati, Susan M. Isaacs, David W. Powell, Michael Merchant, **Jon B. Klein**. American Society of Nephrology 2010 Renal Week [SA-PO2591]

121. Diabetes and High Protein Concentrations Alter Nrf2 Phosphorylation in Renal Tubule Cells
Michelle T. Barati, Susan M. Isaacs, **Jon B. Klein**. American Society of Nephrology 2010 Renal Week [PUB053]
122. Altered Wnt/ β -catenin Pathway and Association of β -catenin with CHOP in Tubules of Diabetic Mice
American Society of Nephrology 2011 Renal Week [SA-PO2591]
123. Differential Regulation of Tubule Endoplasmic Reticulum Chaperones in OVE26 Type I Diabetic Mice :
Michelle T. Barati, Ph.D., Susan M. Isaacs, **Jon B. Klein**, M.D., Ph.D. American Society of Nephrology 2012 Renal Week [TH-PO485]
124. Role of Bradykinins in Renal Development of Diabetic Complications.
Syed J. Khundmiri, Ph.D., Michael Merchant, Ph.D., **Jon B. Klein**, M.D., Ph.D. American Society of Nephrology 2012 Renal Week [TH-PO847]
125. Regulation of Tubule Cell Nrf2 Phosphorylation by Diabetes and High Protein Concentrations.
Michelle T. Barati, Ph.D., Susan M. Isaacs, Jason R. Parks, Abuhusnain S. Khundmiri, **Jon B. Klein**, M.D., Ph.D.. American Society of Nephrology 2012 Renal Week [FR-PO088]
126. Identification of Urine Biomarkers of Lupus Nephritis: CKD Biomarkers Consortium. **Jon B. Klein**, M.D., Ph.D., Michael Merchant, Ph.D., Huijuan Song, Xiaolan Zhang, Ph.D., Alison Marie McKinley Neal, Brad H. Rovin, M.D. American Society of Nephrology 2012 Renal Week [SA-PO754].
127. Identification of Candidate Target Antigens for Membranous Lupus Nephritis. Dawn J. Caster, M.D., Erik Korte, Michael Merchant, Ph.D., Brad H. Rovin, M.D., FASN, John Barker Harley, Bahram Namjou, **Jon B. Klein**, M.D., Ph.D., Kenneth R. McLeish, M.D., David W. Powell, Ph.D.. American Society of Nephrology 2012 Renal Week [SA-PO754].
128. Biomarkers of Interstitial Kidney Pathology in Lupus Nephritis – THE CKD Biomarker Consortium. Brad H. Rovin, M.D., F.A.S.N., Huijuan Song, Cassandra L. Hines, Haifeng M. Wu, M.D., Vasam S. Ramachandran, Paul L. Kimmel, M.D., F.A.S.N., John W. Kusek, Ph.D., Harold I. Feldman, M.D., F.A.S.N., Michael Merchant, Ph.D., **Jon B. Klein, M.D., Ph.D.** American Society of Nephrology 2013 Renal Week. [SA-PO803].
129. Patterns of Circulating Autoantibodies in Patients with Lupus Nephritis. Dawn J. Caster, M.D., Daniel J. Birmingham, Ph.D., Ami S. Joglekar, M.D., **Jon B. Klein, M.D., Ph.D.**, John Barker Harley, Erik Korte, Brad H. Rovin, M.D., F.A.S.N., Kenneth R. McLeish, M.D., David W. Powell, Ph.D. American Society of Nephrology 2013 Renal Week. [RF-PO894].
130. Urinary Monocyte Chemotactic Protein-1 and Early Diabetic Nephropathy (DN) Lesions. Michael Mauer, M.D., Brad H. Rovin, M.D., F.A.S.N., Jon B. Klein, M.D., Ph.D., Vasam S. Ramachandran, Harold I. Feldman, M.D., F.A.S.N., Paul L. Kimmel, M.D., F.A.S.N., John W. Kusek, Ph.D., Robert G. Nelson, M.D., Ph.D. American Society of Nephrology 2013 Renal Week. [SA-OR074].
131. Identification of Thrombospondin Type 1 Domain Containing 7A as a Novel Antigen in Idiopathic Membranous Nephropathy. Nicola M. Tomas, Laurence H. Beck, Catherine Meyer-Schwesinger, Barbara Seitz-Polski, Hong Ma, Gunther Zahner, Guillaume Dolla, Elion Hoxha, Udo Martin

Helmchen, Michael Merchant, **Jon B. Klein**, David J. Salant, Rolf A. Stahl, Gerard J. Lambeau.
American Society of Nephrology 2014 Renal Week

132. Optimization of Identification of the Glomerular Extracellular Matrix Proteome. Liliane Hobeika, M.D., Michelle T. Barati, Ph.D., **Jon B. Klein, M.D., Ph.D.**, Kenneth R. McLeish M.D., Michael Merchant, Ph.D. American Society of Nephrology 2015 Renal Week. [FR-PO304].
133. Plasma Bradykinin and Early Diabetic Nephropathy in Type 1 Diabetes Mellitus. E. Jennifer Weil, M.D., Gudeta D. Fufaa, Ph.D., Robert G. Nelson, M.D., Ph.D., Michael Merchant, Ph.D., Brad H. Rovin, M.D., F.A.S.N., Michael Mauer, M.D., **Jon B. Klein, M.D., Ph.D.** American Society of Nephrology 2015 Renal Week. [FR-PO613].
134. Serial Hepcidin Concentrations in Incident and Prevalent Hemodialysis Subjects Relating to ESA Response. Michael E. Brier, Ph.D., Michael Merchant, Ph.D., Xiaolan Zhang, Ph.D., Jonathan Himmelfarb, M.D., F.A.S.N., Brad H. Rovin, M.D., F.A.S.N., **Jon B. Klein, M.D., Ph.D.** American Society of Nephrology 2015 Renal Week. [FR-PO805].
135. Role of Proteolytic Fragment of suPAR D2-D3 in Prediction and Cause of FSGS. Sanja Sever, Ph.D., Marina V. Kasaikina, Ph.D., Eileen Klapples, Jian Cai, Ph.D., **Jon B. Klein, M.D., Ph.D.**, Nada Alachkar, M.D., David Changli Wei, M.D., Ph.D., Changkyu Gu, Ph.D., Jochen Reiser, M.D., Ph.D. American Society of Nephrology 2015 Renal Week. [FR-PO513].
136. Alternative Complement Components as Predictors of Acute Kidney Injury Risk. Michael Merchant, Ph.D., Michael E. Brier, Ph.D., Emily F. Anggelis, A.P.N., **Jon B. Klein, M.D., Ph.D.** Kenneth R. McLeish, M.D. American Society of Nephrology 2015 Renal Week. [TH-PO118].
137. Methods to Detect Candidate Serum Biomarkers of ESA Resistance. Michael Merchant, Ph.D., Steven Alan Hawkins, Daniel Wade Wilkey, Dusmita Datta, Ph.D., Brad H. Rovin, M.D., F.A.S.N., **Jon B. Klein, M.D., Ph.D.**, Jonathan Himmelfarb, M.D., F.A.S.N., Michel E. Brier, Ph.D. American Society of Nephrology 2015 Renal Week. [TH-PO832].
138. Moesin is a Target of Autoantibodies in Proliferative Lupus Nephritis. Dawn J. Caster, M.D., Erik Korte, Ryan M. Sheehan, Rachel Therese G'Sell, **Jon B. Klein, M.D., Ph.D.**, Michael Merchant, Ph.D., Michelle T. Barati, Ph.D., Brad H. Rovin, M.D., F.A.S.N., Daniel J. Birmingham, Ph.D., Bahram Namjou, Kenneth R. McLeish, M.D., David W. Powell, Ph.D. American Society of Nephrology 2015 Renal Week. [TH-PO331].
139. Identification of Thrombospondin Type 1 Domain Containing 7A as a Novel Antigen in Idiopathic Membranous Nephropathy. Nicola M. Tomas, M.D., Laurence H. Beck, M.D., Ph.D., Caterine Meyer-Schwesinger, M.D., Barbara Seitz-Polski, M.D., Ph.D., Hong Ma, Ph.D., Gunther Zahner, Ph.D., Guillaume Dolla, Elion Hoxha, M.D., Udo Martin Helmchen, M.D., Michael Merchant, Ph.D., **Jon B. Klein, M.D., Ph.D.**, David J. Salant, M.D., Rolf A. Stahl, M.D., Gerard J. Lambeau, Ph.D. American Society of Nephrology 2015 Renal Week. [TH-OR071].
140. Identification of Tissue Biomarkers Differentiating Primary IgA Nephropathy from Staphylococcus Infection Related Glomerulonephritis. Anjali A. Satoskar, M.D., Samir Parikh, M.D., Paul L. Yu, Tibor Nadasdy, M.D., Ph.D., Michael Merchant, Ph.D., **Jon B. Klein, M.D., Ph.D.**, Brad H. Rovin, M.D., F.A.S.N. American Society of Nephrology 2015 Renal Week. [SA-PO493].

141. Minichromosome Maintenance Protein 3 Associates with and Regulates Nrf2 in Proximal Tubules. Michelle T. Barati, Ph.D., Eric Poulos, Whitney L. Ward, Susan M. Isaacs, Madhavi J. Rane, Ph.D., **Jon B. Klein, M.D., Ph.D.**, Michael Merchant, Ph.D. American Society of Nephrology 2015 Renal Week. [SA-OR029].

PUBLICATIONS

Articles (Peer Reviewed):

1. **Klein JB**, McLeish K, Hodsden J, Lordon R: Hypertrophic cardiomyopathy: an acquired disorder of end stage renal disease. *Proceedings of the American Society of Artificial Internal Organs* 29:120-123, 1983.
2. Gray LA, Slater AD, **Klein JB**: A successful cardiac transplantation program using combined university and community resources. *Annals of Surgery* 205:719- 726, 1987.
3. Slater AD, **Klein JB**, Gray LA: Clinical orthotopic cardiac transplantation. *American Journal of Surgery* 153:582-593, 1987.
4. **Klein JB**, McLeish KR, Sonnenfeld G, Dean WL: Potential mechanisms of cytosolic calcium modulation in interferon-treated U937 cells. *Biochem. Biophys. Res. Commun.* 145:1295-1301, 1987.
5. Palakurthy PR, Iyer V, **Klein J**: Amiodarone induced encephalopathy and diabetes insipidus. *J. Ky. Med. Assoc.* 85(7):373-374, July 1987.
6. **Klein JB**, McLeish KR, Bunke CM, Chang B, Ganzel BL, Slater AD, Gray LA: Use of OKT3 monoclonal antibody in the treatment of acute cardiac allograft rejection. *Transplantation* 45:727-729, 1988.
7. Spann CR, Callen JP, **Klein JB**, Kulick KB: Clinical, serologic and immunogenetic studies in patients with chronic cutaneous (discoid) lupus erythematosus who have verrucous and/or hypertrophic skin lesion. *J. Rheumatol* 15:256-261, 1988.
8. **Klein JB**, Brohm JR, McLeish KR: Sustained periods without rejection following treatment of cardiac allograft recipients with OKT3. *Transplantation Proc* 20 [Suppl 1]: 260-262, 1988.
9. Callen JP, **Klein JK**: Subacute cutaneous lupus erythematosus: Clinical, serologic, immunogenetic and therapeutic considerations in seventy-two patients. *Arthritis Rheumatism* 31: 1007-1010, 1988.
10. **Klein JB**: Immune monitoring in the monoclonal era. *Clinical Transplantation.* 2: 177-179, 1988.
11. **Klein JB**: The role of calcium and related message systems in the interferon- γ induced expression of surface antigens on U937 cells. *Doctor of Philosophy Dissertation*, May 1988.

12. Klein LR, **Klein JB**, Hanno R, Callen JP: Mast cell quantity in pruritus of renal failure. *International J Dermatology* 27:557-559, 1988.
13. Mavroudis C, Harrison H, **Klein JB**, Gray LA, Ganzel BL, Wellhausen SR, Elbl F, Cook LN: Infant orthotopic heart transplantation. *J. Thoracic Cardiovas Surg* .96:912-924, 1988.
14. Ganzel TM, Brohm J, Nechtman CM, Ganzel BL, **Klein JB**, Gray LA: Otolaryngologic problems in cardiac transplant patients. *Laryngoscope* 99:158, 1989.
15. **Klein JB**, Schepers TM, Dean WL, Sonnenfeld G, McLeish KR: Role of intracellular calcium concentration and protein kinase C activation in IFN-gamma stimulation of human U937 cells. *J. Immunology* 144:4305-4311. 1990.
16. Holtman JH, Neustadt DH, **Klein J**, Callen JP: Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C₂ deficiency. *Journal of Rheumatology* 17:1222- 1225, 1990.
17. **Klein JB**, Payne V, Schepers TM, McLeish KR: Bacterial lipopolysaccharide enhances polymorphonuclear leukocyte function independent of changes in intracellular calcium. *Inflammation* 14(5):599-611, 1990.
18. Duncan AG, Richardson JB, **Klein JB**, Woodcock TM, Callen JP: Clinical, serologic, and immunogenetic studies in patients with dermatomyositis. *Acta Dermato- Venereologica* 71:312-316, 1990.
19. **Klein JB**, Scherzer JA, McLeish KR: Interferon- γ enhances superoxide production by HL-60 cells stimulated with multiple agonists. *Journal of Interferon Res.* 11:69-74, 1991.
20. **Klein JB**, Sonnenfeld G, McLeish KR: Priming of the HL-60 cell respiratory burst response by tumor necrosis factor- α . *Lymphokine Cytokine Res.* 10(3):173-176, 1991.
21. McLeish KR, **Klein JB**, Schepers T, Sonnenfeld G: Modulation of transmembrane signalling in HL-60 granulocytes by tumor necrosis factor- α . *Biochem J.* 279:455-460, 1991.
22. **Klein JB**, Scherzer JA, McLeish KR: IFN-gamma enhances expression of formyl peptide receptors and guanine nucleotide binding proteins by HL-60 granulocytes. *J. Immunology* 148(8):2483-2488, 1992.
23. Slater AD, **Klein JB**, Sonnenfeld G, Ogden LL, Gray LA: The effects of interferon alpha beta in a model of rat heart transplantation. *Journal of Heart and Lung Transplant* 11(5):975-978, 1992.
24. Schepers TM, **Klein JB**, Feldhoff PW, Dean WL, McLeish KR: Interferon- γ induces phosphorylation of multiple small-molecular-weight proteins in U937 cells. *Journal of Interferon Res.* 12(4):289-296, 1992.
25. Erbeck K, **Klein JB**, McLeish KR: Differential uncoupling of chemoattractant receptors from G proteins in retinoic acid-differentiated HL-60 granulocytes. *J. Immunology* 150(5):1913-1921, 1993.

26. Atala A, Steinbock GS, Harty JI, **Klein JB**: Extracorporeal shock-wave lithotripsy in transplanted kidney. *Urology* 41(1):60-62, 1993.
27. Tanner MK, Wellhausen SR, **Klein JB**: Flow cytometric analysis of altered mononuclear cell transmembrane potential induced by cyclosporin. *Cytometry* 14(1):59-69, 1993.
28. Bunke M, Ganzel B, **Klein JB**, Oldfather J: The effect of a positive B cell crossmatch on early rejection in cardiac transplant recipients. *Transplantation* 56(6):1595-1597, 1993.
29. Slater AD, **Klein JB**, Czarniecki CW, Sonnenfeld G: The effect of interferon- γ on rejection following transplantation. *J. Interferon Res* 13(5):359-362, 1993.
30. Slater AD, **Klein JB**, Czarniecki CW, Sonnenfeld G: The effect of interferon- γ on rejection and neutrophil function following transplantation. *J. Interferon Res* 13(5):359-362, 1993.
31. McLeish KR, Lederer ED, **Klein JB**: Role of isoprenoid metabolism in chemotactic peptide receptor-mediated G protein activation. *Biochem Biophys Res Commun* 197(2):763-770, 1993.
32. Miller ES, Koebel A, Davis S, McLeish KR, **Klein JB**, Goldwater D, Sonnenfeld G: Effect of suspension on neutrophil function in the rat. *J. Appl Physiol* 76:387, 1994.
33. McLeish KR, Lederer ED, **Klein JB**, Hoffman JL: Effect of prenylcysteine analogues on chemoattractant receptor-mediated G protein activation. *Cell Signaling* 6(5):569-579, 1994.
34. **Klein JB**, Jacobs AA, Scherzer JA, McLeish KR: TNF- α stimulates increased plasma membrane guanine nucleotide binding protein activity in polymorphonuclear leukocytes. *J. Leukocyte Biol* .57:500-506, 1995.
35. Jacobs AA, Huber JL, Ward RA, **Klein JB**, McLeish KR: Chemoattractant receptor-specific differences in G protein activation rates regulate effector enzyme and functional responses. *J. Leukocyte Biol* 57:679-686,1995.
36. Barone G, Bunke CM, Choc MG, Hricik DE, Jin J, **Klein JB**, Marsh CL, Min DI, Pescovitz M.D., Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL: The Safety and Tolerability of Cyclosporine Emulsion Versus Cyclosporine in a Randomized, Double-Blind Comparison in Primary Renal Allograft Recipients. *Transplantation* 61:968-987, 1996
37. Barone G, Chang CT, Choc MG, **Klein JB**, Marsh CL, Meligeni JA, Min DI, Pescovitz M.D., Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, Waid Th, Wombolt DG, Wong RL: The Pharmacokinetics of a Microemulsion Formulation of Cyclosporine in Primary Renal Allograft Recipients. *Transplantation* 61:875-880, 1996.
38. Barone G, Chang CT, Choc MG, **Klein JB**, Marsh CL, Meligeni JA, Min DI, Pescovitz MA, Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL: The

- pharmacokinetics of a) microemulsion formulation of cyclosporine neoral™ in primary renal allograft recipients. *Transplantation*. 61:875-80, 1996
39. Barone G, Bunke CM, Choc MG, Hricik DE, Jin JH, **Klein JB**, Marsh CL, Min DI, Pescovitz M.D., Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL: The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. (The Neoral Study Group). *Transplantation*. 61(6):968-70, 1996.
 40. Barone G, Choc MG, Hricik DE, Jin JH, **Klein JB**, Min DI, Pescovitz M.D., Pollak R, Pruett, TL, Stinson JB, Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL (The Neoral Study Group). Safety and tolerability of Neoral^R vs. Sandimmune^R: 1-year data in primary renal allograft recipients. *Transplant Proc*. Aug; 28(4):2183-6, 1996.
 41. McLeish KR, **Klein JB**, Lederer ED, Head KZ, Ward RA, Azotemia, TNF alpha, and LPS prime the human neutrophil oxidative burst by distinct mechanisms. *Kidney Int*. Aug; 50(2): 407-416, 1996.
 42. Pescovitz M.D., Barone G, Choc MG, Jr, Hricik DE, Hwang DS, Jin HJ, **Klein JB**, Marsh CL, Min DI, Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL, Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year data in primary renal allograft recipients: a report of the Neoral Study Group. *Transplantation* 63 (5):778-780, 1997.
 43. Scherzer JA, Ling Y, McLeish KR, and **Klein JB**. Tumor Necrosis Factor-Translational Modulates the Expression of G Protein α_{i2} Subunits in Human Polymorphonuclear Leukocytes. *J. Immunol.* 158(2):913-918, 1997.
 44. Rane, MJ, Carrithers, SL, Arthur, JM, **Klein JB**, and McLeish, KR. Formyl peptide receptors are coupled to multiple mitogen-activated protein kinase cascades by distinct signal transduction pathways. Role in activation of reduced nicotinamide dinucleotide oxidase. *J. Immunol.* 159(10): 5070-5078, 1997.
 45. Lederer ED, Sohi SS, Mathiesen JM, **Klein JB**. Regulation of expression of type II sodium-phosphate cotransporters by protein kinases A and C. *Am J Physiol* 275(2 Pt 2): F270-F277, 1998.
 46. McLeish KR, Knall C, Ward RA, Gerwins P, Coxon PY, **Klein JB**, Johnson GL, Activation of mitogen-activated protein kinase cascades during priming of human neutrophils by TNF-alpha and GM-CSF. *J. Leukoc Biol*. 64(4): 537-545, 1998.
 47. McLeish, KR, **Klein JB**, Head, KZ, and Ward, RA. Bacterial phagocytosis activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in human neutrophils. *J. Leukoc Biol* 64: 835-844, 1998
 48. Kettritz, R, Xu, Y-X, Kerren, T, Quass, P, **Klein JB**, Luft, FC, Haller, H. Extracellular Matrix Regulates Apoptosis in Human neutrophils. *Kidney International* 1999 Feb;55(2):562-71.

49. **Klein, JB**, McLeish, KR, and Ward, RA. Transplantation, not dialysis, corrects azotemia dependent priming of the neutrophil oxidative burst. *Amer. J. Kidney Dis.* 33: 483-491, 1999.
50. Shrotri MS, Kuhn JF, Peyton JC, Flodgaard HJ, **Klein JB**, Cheadle WG. Heparin-binding protein decreases apoptosis in human and murine neutrophils. *J. Surg Res.* 89(1):53-59. March, 2000
51. **Klein, JB**, Rane, MJ, Scherzer, JA, Coxon, PY, Kettritz, R., Mathiesen, JM, Buridi, A, McLeish, KR. Granulocyte-Macrophage colony-stimulating factor delays neutrophil constitutive apoptosis through phosphoinositide 3-kinase and extracellular signal-regulated kinase pathways. *J. Immunol.* 164: 4286-4291: 2000
52. Ralph Kettritz, Ya-Xin Xu, Bettina Faass, **Jon B. Klein**, Eva C. Müller, Albrecht Otto, Andreas Busjahn, Friedrich C. Luft, and Hermann Haller. TNF α -mediated neutrophil apoptosis involves Ly-GDI, a Rho GTPase regulator. *J. Leukoc Biol.* 68: 277-283: 2000
53. Y. James Kang, Zhan-Xiang Zhou, Guang-Wu Wang, Abdul Buridi and **Jon B. Klein**. Suppression by Metallothionein of Doxorubicin-induced Cardiomyocyte Apoptosis through Inhibition of p38 Mitogen-activated Protein Kinases. *J. Biol Chem.*, 275:13690-13698. 2000
54. Y. James Kang, Zhan-Xiang Zhou, Guang-Wu Wang, Abdul Buridi and **Jon B. Klein**. Metallothionein inhibits myocardial apoptosis in copper-deficient mice: Role of atrial natriuretic peptide. *Lab. Invest.* 80:745-747. 2000
55. Cai, L, **Klein, JB**, Kang, YJ: Metallothionein inhibits peroxynitrite-induced DNA and lipoprotein damage. *J. Biol. Chem.*, 275:38957-38960, 2000
56. Coxon, PY, Rane, MJ, Powell, DW, **Klein, JB**, and McLeish, KR. Fc receptor-dependent regulation of human neutrophils by mitogen-activated protein kinases. *J. Immunol.* 164:6530-6537.
57. **Klein, JB**, Buridi, A, Coxon, PY, Rane, MJ, Manning, T, Kettritz, R, McLeish, KR. Role of Extracellular Signal-Regulated Kinase and Phosphatidylinositol 3-Kinase in Chemoattractant and LPS Delay of Constitutive Neutrophil Apoptosis. *Cell Signaling* 13 (5) 335-343, May 2001
58. Rane, MJ, Coxon, PY, Powell, D, Webster, R, **Klein, JB**, Ping, PP, McLeish, KR. p38 kinase-dependent MAPKAPK-2 Activation functions as PDK2 for Akt in human neutrophils. *J. Biol. Chem.* 276:3517-3523. 2001.
59. **Klein, JB**, Buridi, A, Coxon, PY, Rane, MJ, Manning, T, Kettritz, R, and McLeish, KR. Role of extracellular signal-regulated kinase and phosphatidylinositol-3 kinase in chemoattractant and LPS delay of constitutive neutrophil apoptosis. *Cell Signal.* 13:335-343. 2001.
60. Wang, G-W, **Klein, JB**, Kang, JY. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. *J. Pharm. Exp. Therap.* 298:461-468. 2001

61. Vondriska, TM., **Klein, JB**, Ping,P: Use of functional proteomics to investigate PKC{epsilon}- mediated cardioprotection: the signaling module hypothesis. *Am J Physiol Heart Circ Physiol.* 280:H1434-1441. 2001.
62. Thongboonkerd, Visith, McLeish, Kenneth R, Arthur, John M, **Klein, Jon B.** Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. *Kidney International* (2002) Vol 62: 1461-1469
63. **Klein, JB**, Harding, G and Klein, E: A New Isoelectric Focusing Gel for Two-Dimensional Electrophoresis Constructed in Microporous Hollow Fiber Membranes. *J. Proteome Res.* 1), 41 - 45, 2002
64. Song C, Vondriska Tm, Wang GW, **Klein, JB**, Cao X, Zhang J, Kang YJ, D'Souza S, Ping P. Molecular conformation dictates signaling module formation: example of PKCepsilon and Src tyrosine kinase. *Am J Physiol Heart Cir Physiol* 282:H1166-1171, 2002.
65. Molestina, RE, **Klein, JB**, Miller, RD, Ramirez, JA, Pierce, W, Summersgill, JT. Proteomic Analysis of differentially expressed *Chlamydia pneumoniae* proteins during persistent Infection of HEp-2 cells. *Infection and Immunity* 6/2002 2976-2981
66. Castegna, A. Aksenov, M. Aksenova, M., Thongboonkerd, V. **Klein, JB**. Pierce, MW, Booze, R. Markesbery, WR., Butterfield, DA. Proteomic identification of oxidatively modified proteins in alzheimer's disease brain. part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. *Free Radic Biol Med* 2002 Aug 15;33(4):562
67. Thongboonkerd V, Gozal E, Sachleben LR Jr, Arthur JM, Pierce WM, Cai J, Chao J, Bader M, Pesquero JB, Gozal D, **Klein JB**. Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia- induced hypertension. *J. Biol Chem.* 2002 Sep 20;277(38):34708-16.
68. Kettritz, R, Choi, M, Butt, W, Rane, M, Rolle, S, Luft, FC, **Klein, JB**. Phosphatidylinositol 3-kinase controls antineutrophil cytoplasmic antibodies-induced respiratory burst in human neutrophils. *J Am Soc Nephrol* 2002 Jul;13(7):1740-9
69. Thongboonkerd, V, Luengpailin, J, Cao, J, Pierce, WM, Cai, J, **Klein, JB**, and Doyle RJ. Fluoride exposure attenuates expression of streptococcus pyogenes virulence factors. *J Biol Chem.* 2002 May 10;277(19):16599-605
70. **Jon Klein**, George Harding, and Elias Klein. A new isoelectric focusing gel for two-dimensional electrophoresis constructed in microporous hollow fiber membranes. *J Proteome Res.* 2002 Jan;1(1):41-45
71. Changxu Song, Thomas M. Vondriska, Guang-Wu Wang, **Jon B. Klein**, Xinan Cao, Jun Zhang, Y. James Kang, Stanley D'Souza, and Peipei Ping . Molecular conformation dictates signaling module formation: example of PKCepsilon and Src tyrosine kinase. *Am J Physiol Heart Circ Physiol* 2002 Mar;282(3):H1166-71
72. Evelyne Gozal, David Gozal, William M. Pierce, Visith Thongboonkerd, Janice A. Scherzer, Leroy R. Sachleben Jr., Shang-Z. Guo, Jian Cai, and **Jon B. Klein**. Proteomic Analysis of CA1 and CA3 Regions

- of Rat Hippocampus and Differential Susceptibility to Intermittent Hypoxia. *J Neurochem* Oct;83(2):331-45 2002.
73. John M. Arthur, Visith Thongboonkerd, Janice A. Scherzer, Jian Cai, William M. Pierce and **Jon B. Klein**. Differential Expression of Proteins in Renal Cortex and Medulla: A Proteomic Approach. *Kidney International* Oct;62(4):1314-21, 2002.
 74. Castegna, A., Aksenov, M., Thongboonkerd, M., **Klein, JB**, Pierce, W. M., Booze, R., Markesbery, W. R. and Butterfield, D.A. *Proteomic Identification of Oxidatively Modified Proteins in Alzheimer's disease Brain. Part II: dihydropyrimidinase-related protein 2, α -enolase and heat shock cognate 71. *J. Neurochem.* 2002 Sep;82(6):1524-32.
 75. **Klein, JB**, Wang, G-W, Zhianxiang, Z, Buridi, A, Kang, YJ: Inhibition of Tumor Necrosis Factor- α -Dependent Cardiomyocyte Apoptosis by Metallothionein. *Cardiovascular Toxicology* 2(3), 209-217, 2002.
 76. Molestina, Robert E; **Klein, Jon B**; Miller, Richard D; Pierce, William H; Ramirez, Julio A; Summersgill, James T Proteomic analysis of differentially expressed Chlamydia pneumoniae genes during persistent infection of HEp-2 cells. *Infection and Immunity* Vol. 70, Iss. 6, June, 2002, 2976-2981.
 77. Thongboonkerd, V, **Klein, JB**, Arthur JM: Sodium Loading Changes Urinary Protein Excretion: A Proteomic Analysis. *Am J Physiol Renal Physiol.* 284(6):F1155-F1163, 2003.
 78. Rane MJ, Pan, Y, Singh, S, Powell, DW, Wu, R, Cummins, T, Chen, Q, McLeish, KR, **Klein JB**. Heat shock protein 27 controls apoptosis by regulating Akt activation. *J. Biol Chem.* 2003 Jul 25;278(30):27828-35.
 79. Chen Q, Powell DW, Rane MJ, Singh S, Butt W, **Klein JB**, McLeish KR. Akt Phosphorylates p47(phox) and Mediates Respiratory Burst Activity in Human Neutrophils. *J. Immunology* May 15;170(10):5302-8, 2003.
 80. Castegna, A., Thongboonkerd, V., **Klein JB**, Lynn, B., Markesbery, W. R., Butterfield, D.A.: Proteomic Identification of Nitrated Proteins in Alzheimer's Disease Brain. *J Neurochem.* 2003 Jun;85(6):1394-1401.
 81. Zhang SX, Gozal D, Sachleben LR Jr, Rane M, **Klein JB**, Gozal E. Hypoxia induces an autocrine-paracrine survival pathway via platelet-derived growth factor (PDGF)-B/PDGF-beta receptor/phosphatidylinositol 3-kinase/Akt signaling in RN46A neuronal cells. *FASEB J.* 2003 Sep;17(12):1709-11. .
 82. Powell DW, Rane MJ, Joughin BA, Kalmukova R, Hong JH, Tidor B, Dean WL, Pierce WM, **Klein JB**, Yaffe MB, McLeish KR. Proteomic identification of 14-3-3zeta as a mitogen-activated protein kinase-activated protein kinase 2 substrate: role in dimer formation and ligand binding. *Mol Cell Biol.* 2003 Aug;23(15):5376-87.
 83. **Klein JB**, Gozal, D., Pierce, W.M., Thongboonkerd, V., Scherzer, J.A., Sachleben Jr., L.R., Guo, S.-Z., Cai, J., and Gozal, E. Proteomic Identification of a novel protein regulated CA1 and CA3

- hippocampal regions during intermittent hypoxia. *J. Resp Physiology and Neurobiology* 2003 Jul 16;136(2-3):91-103.
84. Singh S, Powell DW, Rane MJ, Millard TH, Trent JO, Pierce WM, **Klein JB**, Machesky LM, McLeish KR. Identification of the p16-Arc subunit of the Arp 2/3 complex as a substrate of MAPK-activated protein kinase 2 by proteomic analysis. *J. Biol Chem.* 2003 Sep 27;278(38):36410.
 85. Thongboonkerd V, Barati MT, McLeish KR, Benarafa C, Remold-O'Donnell E, Zheng S, Rovin BH, Pierce WM, Epstein PN, **Klein JB**. Alterations in the renal elastin-elastase system in type 1 diabetic nephropathy identified by proteomic analysis. *J Am Soc Nephrol.* 2004 Mar;15(3):650
 86. Castegna, A, Thongboonkerd, V, **Klein JB**, Lynn, BC, Wang, Y-L, Osaka, H., Keiji, W, Butterfield, DA. Proteomic analysis of brain proteins in the gracile axonal dystrophy (*gad*) mouse, a syndrome that emanates from dysfunctional ubiquitin carboxy1-terminal hydrolase L-reveals oxidation of key proteins. *J. of Neurochem* 2004 (88) 1540-1546.
 87. Thongboonkerd V, Barati MT, McLeish KR, Pierce WM, Epstein PN, **Klein JB**. Proteomics and diabetic nephropathy. *Contrib Nephrol.* 2004;141:142-54
 88. Thongboonkerd V, **Klein JB**. Practical bioinformatics for proteomics. *Contrib Nephrol.* 2004;141:79-92.
 89. Klein E, **Klein JB**, Thongboonkerd V. Two-dimensional gel electrophoresis: a fundamental tool for expression proteomics studies. *Contrib Nephrol.* 2004;141:25-39.
 90. **Klein JB**, Thongboonkerd V. Overview of proteomics. *Contrib Nephrol.* 2004;141:1-10.
 91. Thongboonkerd V, Klein E, **Klein JB**. Sample preparation for 2-D proteomic analysis. *Contrib. Nephrol.* 2004;141:11-24.
 92. Thongboonkerd V, **Klein JB**. Proteomics and hypertension. *Contrib. Nephrol.* 2004;141:245-56.
 93. Poon, H.F., Castegna, A., Farr, S.A., Thongboonkerd, V., Lynn, B.C., Banks, W.A., Morley, J.E., **Klein JB**, Butterfield, D.A. Quantitative proteomics analysis of specific protein expression and oxidative modification in aged senescence-accelerated-prone 8 mice brain. *Neuroscience* 2004 (126) 915-926.
 94. Shen X, Zheng S, Thongboonkerd V, Xu M, Pierce WM Jr, **Klein JB**, Epstein PN. Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. *Am J Physiol Endocrinol Metab.* 2004 Nov;287(5):
 95. Kumar GK, **Klein JB**. Analysis of expression and posttranslational modification of proteins during hypoxia. *J Appl Physiol.* 2004 Mar;96(3):1178-86;
 96. Thongboonkerd V, **Klein JB**, Jevans AW, McLeish KR. Urinary proteomics and biomarker discovery for glomerular diseases. *Contrib Nephrol.* 2004;141:292-307.
 97. Poon HF, Farr SA, Thongboonkerd V, Lynn BC, Banks WA, Morley JE, **Klein JB**, Butterfield DA. Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid:

- implications for aging and age-related neurodegenerative disorders. *Neurochem Int.* 2005 Jan;46(2):159-68.
98. Chava B. Pocernich, Debra Boyd-Kimball, H. Fai Poon, Visith Thongboonkerd, Bert C. Lynn, **Klein JB**, Vittorio Calebrese, Avindra Nath and D. Allan Butterfield. Proteomics analysis of human astrocytes expressing the HIV protein Tat. *Molecular Brain Research* Feb. 2005; 133, (2):307-316
 99. Chava B. Pocernich, H. Fai Poon, Debra Boyd-Kimball, Bert C. Lynn, Avindra Nath, **Jon B. Klein** and D. Allan Butterfield. Proteomic analysis of oxidatively modified proteins induced by the mitochondrial toxin 3-nitropropionic acid in human astrocytes expressing the HIV protein tat. *Molecular Brain Research* Feb. 2005; 133, (2):299-306
 100. Perluigi M, Fai Poon H, Hensley K, Pierce WM, **Klein JB**, Calabrese V, De Marco C, Butterfield DA. Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice-A model of familial amyotrophic lateral sclerosis. *Free Radic Biol Med.* 2005 Apr 1;38(7):960-8.
 101. Perluigi M, Poon HF, Maragos W, Pierce WM, **Klein JB**, Calabrese V, Cini C, De Marco C, Butterfield DA. Proteomic analysis of protein expression and oxidative modification in R6/2 transgenic mice - A model of Huntington's disease. *Mol Cell Proteomics.* 2005 Jun 20; Dec;4(12):1849-61.
 102. Pocernich CB, Boyd-Kimball D, Poon HF, Thongboonkerd V, Lynn BC, **Klein JB**, Calebrese V, Nath A, Butterfield DA. Proteomics analysis of human astrocytes expressing the HIV protein Tat. *Brain Res Mol Brain Res.* 2005 Feb 18;133(2):307-16.
 103. Pocernich CB, Fai Poon H, Boyd-Kimball D, Lynn BC, Nath A, **Klein JB**, Butterfield DA. Proteomic analysis of oxidatively modified proteins induced by the mitochondrial toxin 3-nitropropionic acid in human astrocytes expressing the HIV protein tat. *Brain Res Mol Brain Res.* 2005 Feb 18;133(2):299-306.
 104. Boyd-Kimball D, Sultana R, Poon HF, Mohmmad-Abdul H, Lynn BC, **Klein JB**, Butterfield DA. Gamma-glutamylcysteine ethyl ester protection of proteins from Abeta(1-42)-mediated oxidative stress in neuronal cell culture: a proteomics approach. *J Neurosci Res.* 2005 Mar 1;79(5):707-13.
 105. Boyd-Kimball D, Sultana R, Poon HF, Lynn BC, Casamenti F, Pepeu G, **Klein JB**, Butterfield DA. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. *Neuroscience.* 2005;132(2):313-24.
 106. Boyd-Kimball D, Castegna A, Sultana R, Poon HF, Petroze R, Lynn BC, **Klein JB**, Butterfield DA. Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease. *Brain Res Mol Brain Res.* 2005 May 24;1044 (2):206-15.
 107. Boyd-Kimball D, Poon HF, Lynn BC, Cai J, Pierce Jr WM, **Klein JB**, Ferguson J, Link CD, Butterfield DA. Proteomic identification of proteins specifically oxidized in *Caenorhabditis elegans* expressing human Abeta(1-42): Implications for Alzheimer's disease. *Neurobiol Aging.* 2006 Sep;27(9):1239-49

108. Poon HF, Shepherd HM, Reed TT, Calabrese V, Stella AM, Pennisi G, Cai J, Pierce WM, **Klein JB**, Butterfield DA. Proteomics analysis provides insight into caloric restriction mediated oxidation and expression of brain proteins associated with age-related impaired cellular processes: Mitochondrial dysfunction, glutamate dysregulation and impaired protein synthesis. *Neurobiol Aging*. 2006 Jul;27(7):1020-34.
109. Poon HF, Farr SA, Banks WA, Pierce WM, **Klein JB**, Morley JE, Butterfield DA. Proteomic Identification of less oxidized brain proteins in aged senescence-accelerated mice following administration of antisense oligonucleotide directed at the Abeta region of amyloid precursor protein. *Brain Res Mol Brain Res*. 2005 Jul 29;138(1):8-16.
110. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, **Klein JB**, Markesbery WR, Zhou XZ, Lu KP, Butterfield DA. Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis. *Neurobiol Aging*. 2006 Jul;27(7):918-25.
111. Ransom RF, Vega-Warner V, Smoyer WE, **Klein JB**. Differential proteomic analysis of proteins induced by glucocorticoids in cultured murine podocytes. *Kidney International*. 2005 Apr;67(4):1275-85.
112. Rane MJ, Gozal D, Butt W, Gozal E, Pierce WM Jr, Guo SZ, Wu R, Goldbart AD, Thongboonkerd V, McLeish KR, **Klein JB**. gamma-Amino Butyric Acid Type B Receptors Stimulate Neutrophil Chemotaxis during Ischemia-Reperfusion. *J Immunology*. 2005 Jun 1;174(11):7242-9.
113. Poon HF, Hensley K, Thongboonkerd V, Merchant ML, Lynn BC, Pierce WM, **Klein JB**, Calabrese V, Butterfield DA. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice—a model of familial amyotrophic lateral sclerosis. *Free Radic Biol Med*. 2005 Aug 15;39(4):453-62.
114. **Klein JB**, Barati MT, Wu R, Gozal D, Sachleben LR Jr, Kausar H, Trent JO, Gozal E, Rane MJ. Akt mediated VCP phosphorylation regulates its association with ubiquitinated proteins. *J Biol Chem*. 2005 Sep 9;280(36):31870-81.
115. Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, **Klein JB**, Markesbery WR, Butterfield DA. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. *Neurobiol Dis*. 2006 Apr;22(1):76-87.
116. Merten KE, Feng W, Zhang L, Pierce W, Cai J, **Klein JB**, Kang YJ. Modulation of cytochrome c oxidase-Va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity. *J Pharmacol Exp Ther*. 2005 Dec;315(3):1314-9.
117. Merchant, M.L., **Klein JB**. Proteomics and Diabetic Nephropathy. *Current Diabetes Reports* 5:464-469.
118. Sultana R, Newman SF, Abdul HM, Cai J, Pierce WM, **Klein JB**, Merchant M, Butterfield DA. Protective effect of D609 against amyloid-beta(1-42)-induced oxidative modification of neuronal proteins: Redox proteomics study. *J Neurosci Res*. 2006 Aug 1;84(2):409-17.

119. Krishna J, Shah ZA, Merchant M, **Klein JB**, Gozal D. Urinary protein expression patterns in children with sleep-disordered breathing: Preliminary findings. *Sleep Med.* 2006 Apr;7(3):221-7
120. Leong PK, Devillez A, Sandberg MB, Yang LE, Yip DK, **Klein JB**, McDonough AA. Effects of ACE inhibition on proximal tubule sodium transport. *Am J Physiol Renal Physiol.* 2006 Apr;290(4):F854-63.
121. Barati MT, Rane MJ, **Klein JB**, McLeish KR. A proteomic screen identified stress-induced chaperone proteins as targets of akt phosphorylation in mesangial cells. *J. Proteome Res.* 2006 Jul;5(7):1636-46.
122. Opii WO, Joshi G, Head E, Milgram NW, Muggenburg BA, **Klein JB**, Pierce WM, CotmanW, Butterfield DA. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: Relevance to Alzheimer's disease. *Neurobiol Aging.* 2006 Oct 19
123. Chen Y, Daosukho C, Opii WO, Turner DM, Pierce WM, **Klein JB**, Vore M, Butterfield DA, St Clair DK. Redox proteomic identification of oxidized cardiac proteins in adriamycin-treated mice. *Free Radic Biol Med.* 2006 Nov 1;41(9):1470-7.
124. Chen Y, Daosukho C, Opii WO, Turner DM, Pierce WM, **Klein JB**, Vore M, Butterfield DA, St Clair DK. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. *Mol Cancer Ther.* 2006 Jul;5(7):1790-9.
125. Lominadze G, Ward RA, **Klein JB**, McLeish KR. Proteomic analysis of human Neutrophils. *Methods Mol Biol.* 2006;332:343-56.
126. G M Boratyn, M L Merchant, and **Klein JB**. Utilization of human expert techniques for detection of low-abundant peaks in high-resolution mass spectra. *Conf Proc IEEE Eng Med Biol Soc.* 2006;1:5798-801
127. Girvan, A. C., Y. Teng, L. K. Casson, S. D. Thomas, S. Juliger, M. W. Ball, **Klein JB**, W.M. Pierce, S. S. Barve, and P. J. Bates. 2006. AGRO100 inhibits activation of nuclear factor- κ B (NF- κ B) by forming a complex with NF- κ B essential modulator (NEMO) and nucleolin. *Mol Cancer Ther.* 2006 Jul;5(7):1790-9.
128. Opii WO, Nukala VN, Sultana R, Pandya JD, Day KM, Merchant ML, **Klein JB**, Sullivan PG, Butterfield DA. "Proteomic Identification of Oxidized Mitochondrial Proteins Following Experimental Brain Injury. *Journal of Neurotrauma* 2007 May;24(5):772-89.
129. Newman SF, Sultana R, Perluigi M, Coccia R, Cai J, Pierce WM, **Klein JB**, Turner DM, Butterfield DA. An increase in S-glutathionylated proteins in the Alzheimer's disease inferior arietal lobule, a proteomics approach. *J. Neurosci Res.* 2007 May 15;85(7): 1506-14.
130. Vaishnav RA, Getchell ML, Poon HF, Barnett KR, Hunter SA, Pierce WM, **Klein JB**, Butterfield DA, Getchell TV. Oxidative stress in the aging murine olfactory bulb: redox proteomics and cellular localization. *J. Neurosci Res.* 2007 Feb 1;85(2):373-85.

131. Sultana R, Boyd-Kimball D, Cai J, Pierce WM, **Klein JB**, Merchant M, Butterfield DA. Proteomics analysis of the Alzheimer's disease hippocampal proteome. *J. Alzheimers Dis.* 2007 May;11(2):153-64.
132. Mello CF, Sultana R, Piroddi M, Cai J, Pierce WM, **Klein JB**, Butterfield DA. Acrolein induces elective protein carbonylation in synaptosomes. *Neuroscience.* 2007 Jul 13;147(3):674-9.
133. Barati MT, Merchant ML, Kain AB, Jevans AW, McLeish KR, **Klein JB**. Proteomic Analysis Defines Altered Cellular Redox Pathways and Advanced Glycation End Product (AGE) Metabolism in Glomeruli of db/db Diabetic Mice. *Am J Physiol Renal Physiol.* 2007 Oct;293(4):F1157-65. 3.
134. Opii WO, Joshi G, Head E, Milgram NW, Muggenburg BA, **Klein JB**, Pierce WM, Cotman CW, Butterfield DA. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: *Neurobiol Aging.* 2008 Jan;29(1):51-70.
135. Vaishnav RA, Getchell ML, Poon HF, Barnett KR, Hunter SA, Pierce WM, **Klein JB**, Butterfield DA, Getchell TV. Oxidative stress in the aging murine olfactory bulb: redox proteomics and cellular localization. *J Neurosci Res.* 2007 Feb 1;85(2):373-85.
136. **Klein JB**, Proteomics and the Kidney: An Evolution. *Seminars in Nephrology*, 11/2007 Vol. 27, Issue 6, Pg 573.
137. Merchant, Michael L, **Klein JB**,. Proteomics and Diabetic Nephropathy. *Semin Nephrol.* 2007 Nov;27(6):627-36.
138. Boratyn GM, Merchant ML, **Klein JB**. Utilization of human expert techniques for detection of low-abundant peaks in high-resolution mass spectra. *Conf Proc IEEE Eng Med Biol Soc.* 2006;1:5798-801.
139. Canter MP, Graham CA, Heit MH, Blackwell LS, Wilkey DW, **Klein JB**, Merchant ML. Proteomic techniques identify urine proteins that differentiate patients with interstitial cystitis from asymptomatic control subjects. *Am J Obstet Gynecol.* 2008 May;198(5):553.e1-6.
140. Reed T, Perluigi M, Sultana R, Pierce WM, **Klein JB**, Turner DM, Coccia R, Markesbery WR, Butterfield DA. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnesic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. *Neurobiol Dis.* 2008 Apr;30(1):107-20.
141. Merchant ML, Cummins T, Wilkey DW, Salyer SA, Powell DW, **Klein JB**, Lederer ED. Proteomic analysis of renal calculi indicates an important role for inflammatory processes in calcium stone formation. *Am J Physiol Renal Physiol.* 2008 Aug 13.
142. Catapano G, **Klein JB**. The times they are a-changing--a year of transition. *International Journal of Artif Organs.* 2008 Dec;31(12):997-1001

143. Canter MP, Graham CA, Heit MH, Blackwell LS, Wilkey DW, **Klein JB**, Merchant ML. Proteomic techniques identify urine proteins that differentiate patients with interstitial cystitis from asymptomatic control subjects. *Am J Obstet Gynecol*. 2008 May;198(5):553.
144. Powell DW, Bertram CC, Cummins TD, Barati MT, Zheng S, Epstein PN, **Klein JB**. Renal Tubulointerstitial Fibrosis in OVE26 Type 1 Diabetic Mice. *Nephron Exp Nephrol* 2009;111:e11-e19
145. Madhavi J. Rane , **Klein JB**. Regulation of neutrophil apoptosis by modulation of PKB/Akt activation. *Frontiers in Bioscience* 14, 2400-2412, January 1, 2009
146. Powell DW, Bertram CC, Cummins TD, Barati MT, Zheng S, Epstein PN, **Klein JB**. Renal tubulointerstitial fibrosis in OVE26 type 1 diabetic mice. *Nephron Exp Nephrol*. 2009;111(1)
147. Tezel TH, Geng L, Lato EB, Schaal S, Liu Y, Dean D, **Klein JB**, Kaplan HJ. Synthesis and secretion of hemoglobin by retinal pigment epithelium. *Invest Ophthalmol Vis Sci*. 2009 Apr;50(4):1911-9
148. Smith C, Merchant M, Fekete A, Nyugen HL, Oh P, Tain YL, **Klein JB**, Baylis C. Splice variants of neuronal nitric oxide synthase are present in the rat kidney. *Nephrol Dial Transplant*. 2009 May;24(5):1422-8
149. Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, **Klein JB**, Ng DP, Placha G, Canani LH, Bochenski J, Waggott D, Merchant ML, Krolewski B, Mirea L, Wanic K, Katavetin P, Kure M, Wolkow P, Dunn JS, Smiles A, Walker WH, Boright AP, Bull SB; DCCT/EDIC Research Group, Doria A, Rogus JJ, Rich SS, Warram JH, Krolewski AS. Genome-wide Association Scan for Diabetic Nephropathy Susceptibility Genes in Type 1 Diabetes Mellitus. *Diabetes*. 2009 Jun;58(6): 1403-10.
150. Rane MJ, **Klein JB**. Regulation of neutrophil apoptosis by modulation of PKB/Akt activation. *Front Biosci*. 2009 Jan 1;14:2400-12
151. Merchant ML, **Klein JB**. Proteomics and diabetic retinopathy. *Clin Lab Med*. 2009 Mar; 29(1):139-49.
152. Merchant ML, Perkins BA, Boratyn GM, Ficociello LH, Wilkey DW, Barati MT, Bertram CC, Page GP, Rovin BH, Warram JH, Krolewski AS, **Klein JB**. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. *J Am Soc Nephrol*. 2009 Sep;20(9): 2065-74
153. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, **Klein JB**, Salant DJ. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. *N Engl J Med*. 2009 Jul 2;361(1):11-21.
154. Catapano G, **Klein JB**. It's the end of the world as we know it* - an era comes to a close. *Int J Artif Organs* 32:831-835, 2009
155. Merchant ML, **Klein JB**. Proteomic discovery of diabetic nephropathy biomarkers. *Adv Chronic Kidney Dis*. 2010 Nov;17(6):480-6.

156. Cummins TD, Barati MT, Coventry SC, Salyer SA, **Klein JB**, Powell DW. Quantitative mass spectrometry of diabetic kidney tubules identifies GRAP as a novel regulator of TGF-beta signaling. *Biochim Biophys Acta*. 2010 Apr;1804(4):653-61
157. Rane MJ, Song Y, Jin S, Barati MT, Wu R, Kausar H, Tan Y, Wang Y, Zhou G, **Klein JB**, Li X, Cai L. Interplay between Akt and p38 MAPK pathways in the regulation of renal tubular cell apoptosis associated with diabetic nephropathy. *Am J Physiol Renal Physiol*. 2010 Jan;298(1):F49-61
158. Merchant ML, Powell DW, Wilkey DW, Cummins TD, Deegens JK, Rood IM, McAfee KJ, Fleischer C, Klein E, **Klein JB**. Microfiltration isolation of human urinary exosomes for characterization by MS. *PROTEOMICS – Clinical Applications* 4:84-96, 2010
159. Rood IM, Deegens JK, Merchant ML, Tamboer WP, Wilkey DW, Wetzels JF, **Klein JB**. Comparison of three methods for isolation of urinary microvesicles to identify biomarkers of nephrotic syndrome. *Kidney Int*, 2010
160. Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, Bennett SE, Bischoff R, Bongcam-Rudloff E, Capasso G, Coon JJ, D'Haese P, Dominiczak AF, Dakna M, Dihazi H, Ehrich JH, Fernandez-Llama P, Fliser D, Frokiaer J, Garin J, Girolami M, Hancock WS, Haubitz M, Hochstrasser D, Holman RR, Ioannidis JP, Jankowski J, Julian BA, **Klein JB**, Kolch W, Luidert T, Massy Z, Mattes WB, Molina F, Monsarrat B, Novak J, Peter K, Rossing P, Sanchez-Carbayo M, Schanstra JP, Semmes OJ, Spasovski G, Theodorescu D, Thongboonkerd V, Vanholder R, Veenstra TD, Weissinger E, Yamamoto T, Vlahou A: Recommendations for biomarker identification and qualification in clinical proteomics. *Sci Transl Med* 2:46ps42, 2010
161. Arthur JM, **Klein JB**. Proteomics in CKD. *Adv Chronic Kidney Dis*. 2010 Nov;17(6):453-4.
162. Merchant ML, Gaweda AE, Dailey AJ, Wilkey DW, Zhang X, Rovin BH, **Klein JB**, Brier ME. Oncostatin M receptor β and cysteine/histidine-rich 1 are biomarkers of the response to erythropoietin in hemodialysis patients. *Kidney Int*. 2011 Mar;79(5):546-54.
163. Ahmad A, Khundmiri SJ, Pribble F, Merchant ML, Ameen M, **Klein JB**, Levi M, Lederer ED. Role of Vacuolar ATPase in the Trafficking of Renal Type IIa Sodium-phosphate Cotransporter. *Cell Physiol Biochem*. 2011;27(6):703-14.
164. Merchant ML, Gaweda AE, Dailey AJ, Wilkey DW, Zhang X, Rovin BH, **Klein JB**, Brier ME. Oncostatin M receptor β and cysteine/histidine-rich 1 are biomarkers of the response to erythropoietin in hemodialysis patients. *Kidney Int*. 2011 Mar;79(5):546-54.
165. Timothy D. Cummins, Michael D. Mendenhall, Michelle N. Lowry, Erik A. Korte, Michelle T. Barati, Syed J. Khundmiri, Sarah A. Salyer, **Jon B. Klein**, David W. Powell. Elongin C is a Mediator of Notch4 Activity in Human Renal Tubule Cells, *Biophys Acta*. 2011 Dec;1814(12):1748-57
166. Fiorini A, Sultana R, Barone E, Cenini G, Perluigi M, Mancuso C, Cai J, **Klein JB**, St Clair D, Butterfield DA. Lack of p53 affects the expression of several brain mitochondrial proteins:

- insights from proteomics into important pathways regulated by p53. *PLoS One*. 2012;7(11):e49846. doi: .1371/journal.pone.0049846.
167. Lederer ED, **Klein JB**. New treatments for CKD--new insights into pathogenesis. *J Am Soc Nephrol*. 2012 Oct;23(10):1601-3. PMID:22975668
168. Catapano G, **Klein JB**. Days* - A bright future on solid foundations. *Int J Artif Organs*. 2012 Feb 11:0. doi: 10.5301/IJAO.2012.9030. [Epub ahead of print] No abstract available. PMID:22328331 Not peer reviewed. Editorial
169. Baba SP, Hoetker JD, Merchant M, **Klein JB**, Cai J, Barski OA, Conklin DJ, Bhatnagar A. Role of aldose reductase in the metabolism and detoxification of carnosine-acrolein conjugates. *J Biol Chem*. 2013 Sep 27;288(39):28163-79. doi: 10.1074/jbc.M113.504753. PMID:23928303
170. Garbett NC, Merchant ML, Chaires JB, **Klein JB**. Calorimetric analysis of the plasma proteome: identification of type 1 diabetes patients with early renal function decline. *Biochim Biophys Acta*. 2013 Oct;1830(10):4675-80.
171. McLeish KR, Merchant ML, **Klein JB**, Ward RA. Technical note: proteomic approaches to fundamental questions about neutrophil biology. *J Leukoc Biol*. 2013 Oct;94(4):683-692. PMID:23470899
172. Merchant ML, Niewczas MA, Ficociello LH, Lukenbill JA, Wilkey DW, Li M, Khundmiri SJ, Warram JH, Krolewski AS, **Klein JB**. Plasma kininogen and kininogen fragments are biomarkers of progressive renal decline in type 1 diabetes. *Kidney Int*. 2013 Jun;83(6):1177-84. PMID:23466993
173. Sultana R, Baglioni M, Cecchetti R, Cai J, **Klein JB**, Bastiani P, Ruggiero C, Mecocci P, Butterfield DA. Lymphocyte mitochondria: toward identification of peripheral biomarkers in the progression of Alzheimer disease. *Free Radic Biol Med*. 2013 Aug 8;65C:595-606. doi: 10.1016/j.freeradbiomed.2013.08.001.
174. Keeney JT, Förster S, Sultana R, Brewer LD, Latimer CS, Cai J, **Klein JB**, Porter NM, Allan Butterfield D. Dietary vitamin D deficiency in rats from middle to old age leads to elevated tyrosine nitration and proteomics changes in levels of key proteins in brain: Implications for low vitamin D-dependent age-related cognitive decline. *Free Radic Biol Med*. 2013 Jul 18;65C:324-334. PMID:23872023
175. Fiorini A, Sultana R, Förster S, Perluigi M, Cenini G, Cini C, Cai J, **Klein JB**, Farr SA, Niehoff ML, Morley JE, Kumar VB, Allan Butterfield D. Antisense directed against PS-1 gene decreases brain oxidative markers in aged senescence accelerated mice (SAMP8) and reverses learning and memory impairment: A proteomics study. *Free Radic Biol Med*. 2013 Jun 15;65C:1-14. PMID:23777706
176. Garbett NC, Merchant ML, Helm CW, Jenson AB, **Klein JB**, Chaires JB. Detection of cervical cancer biomarker patterns in blood plasma and urine by differential scanning calorimetry and mass

- spectrometry. PLoS One. 2014 Jan 8;9(1):e84710. doi: 10.1371/journal.pone.0084710. eCollection 2014. PMID: 24416269.
177. Zhao Y, Miriyala S, Miao L, Mitov M, Schnell D, Dhar SK, Cai J, **Klein JB**, Sultana R, Butterfield DA, Vore M, Batinic-Haberle I, Bondada S, St Clair DK: Redox proteomic identification of HNE-bound mitochondrial proteins in cardiac tissues reveals a systemic effect on energy metabolism after doxorubicin treatment. *Free Radic Biol Med* 2014;
 178. Tomas NM, Beck LH, Jr., Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, Debayle D, Merchant M, **Klein JB**, Salant DJ, Stahl RA, Lambeau G: Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. *N Engl J Med* 2014;371:2277-2287
 179. Garbett NC, Merchant ML, Helm CW, Jenson AB, **Klein JB**, Chaires JB: Detection of cervical cancer biomarker patterns in blood plasma and urine by differential scanning calorimetry and mass spectrometry. *PLoS One* 2014;9:e84710
 180. Zhao Y, Miriyala S, Miao L, Mitov M, Schnell D, Dhar SK, Cai J, **Klein JB**, Sultana R, Butterfield DA, Vore M, Batinic-Haberle I, Bondada S, St Clair DK: Redox proteomic identification of HNE-bound mitochondrial proteins in cardiac tissues reveals a systemic effect on energy metabolism after doxorubicin treatment. *Free Radic Biol Med* 2014
 181. Cenini G, Fiorini A, Sultana R, Perluigi M, Cai J, **Klein JB**, Head E, Butterfield DA: An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach. *Free Radic Biol Med* 2014;76C:89-95
 182. Zhao Y, Miriyala S, Miao L, Mitov M, Schnell D, Dhar SK, Cai J, **Klein JB**, Sultana R, Butterfield DA, Vore M, Batinic-Haberle I, Bondada S, St Clair DK: Redox proteomic identification of HNE-bound mitochondrial proteins in cardiac tissues reveals a systemic effect on energy metabolism after doxorubicin treatment. *Free Radic Biol Med* 2014;72:55-65
 183. Triplett J, Zhang Z, Sultana R, Cai J, **Klein JB**, Bueler H, Butterfield DA: Quantitative Expression Proteomics and Phosphoproteomics Profile of Brain from PINK1 Knockout Mice: Insights into Mechanisms of Familial Parkinson Disease. *J Neurochem* 2015;
 184. Hsu CY, Ballard S, Batlle D, Bonventre JV, Bottinger EP, Feldman HI, **Klein JB**, Coresh J, Eckfeldt JH, Inker LA, Kimmel PL, Kusek JW, Liu KD, Mauer M, Mifflin TE, Molitch ME, Nelsestuen GL, Rebholz CM, Rovin BH, Sabbisetti VS, Van Eyk JE, Vasan RS, Waikar SS, Whitehead KM, Nelson RG, for the CKDBC: Cross-Disciplinary Biomarkers Research: Lessons Learned by the CKD Biomarkers Consortium. *Clin J Am Soc Nephrol* 2015;
 185. Caster DJ, Korte EA, Merchant ML, **Klein JB**, Wilkey DW, Rovin BH, Birmingham DJ, Harley JB, Cobb BL, Namjou B, McLeish KR, Powell DW: Autoantibodies targeting glomerular annexin A2 identify patients with proliferative lupus nephritis. *Proteomics Clin Appl* 2015;
 186. Triplett J, Zhang Z, Sultana R, Cai J, **Klein JB**, Bueler H, Butterfield DA: Quantitative Expression Proteomics and Phosphoproteomics Profile of Brain from PINK1 Knockout Mice: Insights into Mechanisms of Familial Parkinson Disease. *J Neurochem* 2015;

187. Hsu CY, Ballard S, Batlle D, Bonventre JV, Bottinger EP, Feldman HI, **Klein JB**, Coresh J, Eckfeldt JH, Inker LA, Kimmel PL, Kusek JW, Liu KD, Mauer M, Mifflin TE, Molitch ME, Nelsestuen GL, Rebholz CM, Rovin BH, Sabbisetti VS, Van Eyk JE, Vasan RS, Waikar SS, Whitehead KM, Nelson RG, for the CKDBC: Cross-Disciplinary Biomarkers Research: Lessons Learned by the CKD Biomarkers Consortium. *Clin J Am Soc Nephrol* 2015;
188. Caster DJ, Korte EA, Merchant ML, **Klein JB**, Wilkey DW, Rovin BH, Birmingham DJ, Harley JB, Cobb BL, Namjou B, McLeish KR, Powell DW: Autoantibodies targeting glomerular annexin A2 identify patients with proliferative lupus nephritis. *Proteomics Clin Appl* 2015;
189. Caster DJ, Hobeika L, **Klein JB**, Powell DW, McLeish KR: Changing the Concepts of Immune-Mediated Glomerular Diseases through Proteomics. *Proteomics Clin Appl* 2015;
190. Rovin BH, **Klein JB**: Proteomics and autoimmune kidney disease. *Clin Immunol* 2015;
191. Fufaa GD, Weil EJ, Nelson RG, Hanson RL, Knowler WC, Rovin BH, Wu H, **Klein JB**, Mifflin TE, Feldman HI, Vasan RS, Kimmel PL, Kusek JW, Mauer M, Consortium CKDB, the RI: Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus. *Nephrol Dial Transplant* 2015;30:599-606
192. Jin S, Merchant ML, Ritzenthaler JD, McLeish KR, Lederer ED, Torres-Gonzalez E, Fraig M, Barati MT, Lentsch AB, Roman J, **Klein JB**, Rane MJ: Baclofen, a GABABR agonist, ameliorates immune-complex mediated acute lung injury by modulating pro-inflammatory mediators. *PLoS One* 2015;10:e0121637
193. Barati MT, Lukenbill J, Wu R, Rane MJ, **Klein JB**: Cytoskeletal rearrangement and Src and PI-3K-dependent Akt activation control GABA(B)R-mediated chemotaxis. *Cell Signal* 2015;27:1178-1185
194. Triplett JC, Zhang Z, Sultana R, Cai J, **Klein JB**, Bueler H, Butterfield DA: Quantitative expression proteomics and phosphoproteomics profile of brain from PINK1 knockout mice: insights into mechanisms of familial Parkinson's disease. *J Neurochem* 2015;133:750-765
195. Triplett JC, Swomley A, Kirk J, Lewis K, Orr M, Rodriguez K, Cai J, **Klein JB**, Buffenstein R, Butterfield DA: Metabolic clues to salubrious longevity in the brain of the longest-lived rodent: the naked mole-rat. *J Neurochem* 2015;134:538-550
196. Yang X, Hondur G, Li M, Cai J, **Klein JB**, Kuehn MH, Tezel G: Proteomics analysis of molecular risk factors in the ocular hypertensive human retina. *Invest Ophthalmol Vis Sci* 2015;Sep:56(10)16-30.
197. Rood IM, Merchant ML, Wilkey DW, Zhang T, Zabrouskov V, van der Viag J, Dijkman HB, Willemsen BK, Wetzels JF, **Klein JB**, Deegens JK: Increase expression of lysosome membrane protein 2 in glomeruli of patients with idiopathic membranous nephropathy. *Proteomics* 2015: Nov; 15(21)3722-30.
198. Triplett JC, Tramutola A, Swomley A, Kirk J, Grimes K, Lewis K, Orr M, Rodriguez K, Cai J, **Klein JB**, Perluigi M, Buffenstein R, Butterfield DA: Age-related changes in the proteostasis network in the brain of the naked mole-rat: Implications promoting healthy longevity. *Biochim Biophys Acta* 2015:Oct;1852(10 Pt A):2213-2224.

199. Triplett JC, Swomley AM, Kirk J, Grimes KM, Lewis KN, Orr ME, Rodriguez KA, Cai J, **Klein JB**, Buffenstein R, Butterfield DA: Reaching out to send a message: proteins associated with neurite outgrowth and neurotransmission are altered with age in the long-lived naked mole-rat. *Neurochem Res* 2016; Jul;41(7):1625-1634
200. Barati MT, Powell DW, Kechavarizi BD, Isaacs SM, Zheng S, Epstein PN, Cai L, Coventry S, Rane MJ, **Klein JB**: Differential express of endoplasmic reticulum stress-response proteins in different renal tubule subtypes of OVE26 diabetic mice. *Cell stress Chaperones* 2016;Jan:21(1):155-166.
201. Triplett JC, Swomley AM, Cai J, **Klein JB**, Butterfield DA: Quantitative phosphoproteomic analyses of the inferior parietal lobule from three different pathological stages of alzheimer's disease. *J Alzheimers Dis* 2016; 49(1)46-62.
202. Wheelock KM, Cai J, Looker HC, Merchant ML, Nelson RG, Fufaa GD, Weil EJ, Feldman HI, Vasana RS, Kimmel PL, Rovin BH, Mauer M, **Klein JB**: Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus. *CKD Biomarkers Consortium. PLoS One* 2017 Jul 10;12(7)
203. Birmingham DJ, Merchant M, Waikar SS, Nagaraja H, **Klein JB**, Rovin BH. Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise. *Nephrol Dial Transplant.* 2017 Jan 1;32(suppl_1):i71-i79.
204. **Klein JB**. Applying proteomics to detect early signs of chronic kidney disease: where has the magic gone? *Expert Rev Proteomics.* 2017 May;14(5):387-390
205. Swomley AM, Triplett JC, Keeney JT, Warriar G, Pearson KJ, Mattison JA, de Cabo R, Cai J, **Klein JB**, Butterfield DA. Comparative proteomic analyses of the parietal lobe from rhesus monkeys fed a high-fat/sugar diet with and without resveratrol supplementation, relative to a healthy diet: Insights into the roles of unhealthy diets and resveratrol on function. *J Nutr Biochem.* 2017 Jan;39:169-179.
206. Merchant, ML, Rood IM, Deegens JKJ, **Klein JB**: Isolation and characterization of urinary extracellular vesicles: implications for biomarker discovery. *Nat Rev Nephrol.* 2017 Dec;13(12):731-749.
207. Aymé S, Bockenbauer D, Day S, Devuyst O, Guay-Woodford LM, Ingelfinger JR, **Klein JB**, Knoers NVAM, Perrone RD, Roberts J, Schaefer F, Torres VE, Cheung M, Wheeler DC, Winkelmayr WC; Conference Participants. Common elements in rare kidney diseases: conclusions from a kidney disease : improving global outcomes (KDIGO) conference. *Kidney Int.* 2017 Pct;92(4):796-808
208. Arndt DA, Oostveen EK, Triplett J, Allan Butterfield D, Tsyusko OV, Collin B, Stames DL, Cai J, **Klein JB**, Nasws R, Unrine JM. The role of charge in the toxicity of polymer-coated cerium oxide nanomaterials to *Caenorhabditis elegans*. *Comp Biochem Physiol C Toxicol Pharmacol* 2017 Oct;201:1-10.

209. Larsen CP, Trivin-Avillach C, Coles P, Collins AB, Merchant M, Ma H, Wilkey DW, Ambruzs JM, Messias NC, Cossey LN, Rosales IA, Wooldridge T, Walker PD, Colvin RB, **Klein J**, Slant DJ, Beck LH, Jr. LDL receptor-related protein 2 (megalin) as a target antigen in human kidney anti-brush border antibody disease JASN 2017.
210. Wheelock, KM, Cai J, Looker HC, Merchant ML, Nelson RG, Fufaa GD, Weil EJ, Feldman HI, Vasani RS, Kimmel PL, Rovin BH, Mauer M, **Klein JB**. Consortium, CKDB: plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus. PLoSOne 12:e0180964, 2017.
211. Merchant ML, Brier ME, Slaughter MS, **Klein JB**, McLeish KR. Biomarker enhanced risk prediction for development of AKI after cardiac surgery. BMC Nephrology 2018 19:102-110.
212. Caster DJ, Merchant ML, **Klein JB**, Powell DW. Precision medicine in lupus nephritis: can biomarkers get us there? Transl Res. 2018 Aug;S1931-5244(18)
213. Looker HC, Merchant ML, Rane MJ, Nelson RG, Kimmel PL, Rovin BH, **Klein JB**, Mauer M, Consortium CB.. Urine inositol pentakisphosphate 2-kinase and changes in kidney structure in early diabetic kidney disease type 1 diabetes. Am J Physiol Renal Physiol 2018 Aug 22.
214. Tramutola A, Traiani F, Di Domenico F, Barone E, Cai J, **Klein JB**, Perluigi M, Butterfield DA. Poly-ubiquitin profile in Alzheimer disease brain. Neurobiol Dis 2018 Oct;118:129-141.
215. **Klein JB**, Knepper M. Protein mass spectrometry made simple. J Am Soc Nephrol 2018 Jun;29(6):1585-1587
216. Merchant ML, Brier ME, Slaughter MS, **Klein JB**, McLeish KR. Biomarker enhanced risk prediction for development of AKI after cardiac surgery. BMC Nephrol 2018 May2;19(1):102
217. Mariani LH, Bomback AS, Canetta PA, Flessner MF, Helmuth M, Hladunewich MA, Hogan JJ, Kiryluk K, Nachman PH, Nast CC, Rheault MN, Rizk DV, Trachtman H, Wenderfer SE, Bowers C, Hill-Callahan P, Marasa M, Poulton CJ, Revell A, Vento S, Barisoni L, Cattran D, D'Agati V, Jennette JC, **Klein JB**, Laurin, Twombly K, Falk RJ, Gharavi Y, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson B, Smoyer WE, Guay-Woodford LM, CureGN Consortium. CureGN study rationale, design and methods: Establishing a large prospective observational study of Glomerular Disease. AJKD 2019 Feb(2):218-229.
218. Wei C, Li J, Adair BD, Zhu K, Cai J, Merchant M, Samelko B, Liao Z, Koh KH, Tardi NJ, Dande RR, Liu S, Ma J, Dibartolo S, Hagele S, Peev V, Hayek SS, Cimbalk DJ, Tracy M, Klein J, Sever S, Shattil SJ, Aranaout MA, Reiser J. uPAR isoform 2 forms a dimer and induces severe kidney disease in mice. J Clin Invest 2019 129:1946-1959.
219. Weingartner LA, Sawning S, Shaw MA, **Klein JB**. Compassion cultivation training promotes medical student wellness and enhanced clinical care. BMC Med Educ, 2019 May (1) 139.
220. Agrawal S, Merchant ML, Kino J, Li M, Wilkey DW, Gaweda AE, Brier ME, Chanley MA, Gooding JR, Sumner SJ, **Klein JB***, Smoyer WE*; Midwest Pediatric Nephrology Consortium. Predicting and Defining Steroid Resistance in Pediatric Nephrotic Syndrome Using Plasma Proteomics Kidney Int

- Rep. 2019 Sep 19;5(1):66-80. *equal contribution.
221. Gooding JR, Agrawal S, McRitchie S, Acuff Z, Merchant ML, **Klein JB**, Smoyer WE, Sumner SJ; Midwest Pediatric Nephrology Consortium. Predicting and Defining Steroid Resistance in Pediatric Nephrotic Syndrome Using Plasma Metabolomics. *Kidney Int Rep.* 2019 Sep 19;5(1):81-93.
222. Satoskar AA, Shapiro JP, Jones M, Bott C, Parikh SV, Brodsky SV, Yu L, Nagaraja HN, Wilkey DW, Merchant ML, **Klein JB**, Nadasdy T, Rovin BH. Differentiating Staphylococcus infection-associated glomerulonephritis and primary IgA nephropathy: a mass spectrometry-based exploratory study *Sci Rep.* 2020 Oct 14;10(1):17179.
223. Samuel G, Crow J, **Klein JB**, Merchant ML, Nissen E, Koestler DC, Laurence K, Liang X, Neville K, Staggs V, Ahmed A, Atay S, Godwin AK. Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers. *Oncotarget.* 2020 Aug 4;11(31):2995-3012.
224. Merchant ML, Barati MT, Caster DJ, Hata JL, Hobeika L, Coventry S, Brier ME, Wilkey DW, Li M, Rood IM, Deegens JK, Wetzels JF, Larsen CP, Troost JP, Hodgin JB, Mariani LH, Kretzler M, **Klein JB**, McLeish KR. Proteomic Analysis Identifies Distinct Glomerular Extracellular Matrix in Collapsing Focal Segmental Glomerulosclerosis. *J Am Soc Nephrol.* 2020 Aug;31(8):1883-1904.

BOOK CHAPTERS

Rane M and **Klein JB**: Proteomic Analysis of AKT Signaling Complexes. "Functional Proteomics", P. Ping Editor, Humana Press.

Thongboonkerd, V, Klein, E, **Klein JB**: Proteomics in Nephrology. 2004 Contributions to Nephrology Vol. 141